WO2024047172A1 - Conjugué anticorps-médicament d'intégrine alpha10 - Google Patents
Conjugué anticorps-médicament d'intégrine alpha10 Download PDFInfo
- Publication number
- WO2024047172A1 WO2024047172A1 PCT/EP2023/073919 EP2023073919W WO2024047172A1 WO 2024047172 A1 WO2024047172 A1 WO 2024047172A1 EP 2023073919 W EP2023073919 W EP 2023073919W WO 2024047172 A1 WO2024047172 A1 WO 2024047172A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- drug conjugate
- antigen
- binding fragment
- Prior art date
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 235
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 182
- 102100025310 Integrin alpha-10 Human genes 0.000 title abstract description 5
- 108010035006 integrin alpha 10 Proteins 0.000 title abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 253
- 239000012634 fragment Substances 0.000 claims description 201
- 108010044426 integrins Proteins 0.000 claims description 176
- 102000006495 integrins Human genes 0.000 claims description 176
- 239000000427 antigen Substances 0.000 claims description 168
- 108091007433 antigens Proteins 0.000 claims description 168
- 102000036639 antigens Human genes 0.000 claims description 168
- 206010028980 Neoplasm Diseases 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 66
- 239000008194 pharmaceutical composition Substances 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 239000013543 active substance Substances 0.000 claims description 49
- 201000011510 cancer Diseases 0.000 claims description 39
- 230000014509 gene expression Effects 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 36
- 230000001268 conjugating effect Effects 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 28
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 27
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 27
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 27
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 27
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 27
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 26
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 26
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 206010006187 Breast cancer Diseases 0.000 claims description 25
- 208000026310 Breast neoplasm Diseases 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 239000003053 toxin Substances 0.000 claims description 25
- 231100000765 toxin Toxicity 0.000 claims description 25
- 108700012359 toxins Proteins 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 23
- -1 anthracyclines Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 21
- 238000001514 detection method Methods 0.000 claims description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 17
- 229940127089 cytotoxic agent Drugs 0.000 claims description 17
- 208000005017 glioblastoma Diseases 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 16
- 230000000981 bystander Effects 0.000 claims description 15
- 239000002254 cytotoxic agent Substances 0.000 claims description 15
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 15
- 108010030356 CD11a Antigen Proteins 0.000 claims description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 12
- 206010003571 Astrocytoma Diseases 0.000 claims description 11
- 238000013518 transcription Methods 0.000 claims description 11
- 230000035897 transcription Effects 0.000 claims description 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 10
- 230000030833 cell death Effects 0.000 claims description 10
- 201000007455 central nervous system cancer Diseases 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 235000013922 glutamic acid Nutrition 0.000 claims description 10
- 239000004220 glutamic acid Substances 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 9
- 108010016626 Dipeptides Proteins 0.000 claims description 8
- 206010014967 Ependymoma Diseases 0.000 claims description 8
- 102000029749 Microtubule Human genes 0.000 claims description 8
- 108091022875 Microtubule Proteins 0.000 claims description 8
- 206010073334 Rhabdoid tumour Diseases 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 230000008901 benefit Effects 0.000 claims description 8
- 229960004679 doxorubicin Drugs 0.000 claims description 8
- 210000004688 microtubule Anatomy 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 206010027476 Metastases Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 7
- 201000008968 osteosarcoma Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000000700 radioactive tracer Substances 0.000 claims description 7
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 102000005600 Cathepsins Human genes 0.000 claims description 5
- 108010084457 Cathepsins Proteins 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 230000000340 anti-metabolite Effects 0.000 claims description 5
- 230000001946 anti-microtubular Effects 0.000 claims description 5
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 5
- 239000002256 antimetabolite Substances 0.000 claims description 5
- 229940100197 antimetabolite Drugs 0.000 claims description 5
- 239000003080 antimitotic agent Substances 0.000 claims description 5
- 229940034982 antineoplastic agent Drugs 0.000 claims description 5
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 5
- 229960002173 citrulline Drugs 0.000 claims description 5
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 239000000833 heterodimer Substances 0.000 claims description 5
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 5
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000004057 myxopapillary ependymoma Diseases 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 5
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 claims description 4
- 208000000172 Medulloblastoma Diseases 0.000 claims description 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 238000011503 in vivo imaging Methods 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229920001427 mPEG Polymers 0.000 claims description 4
- 210000002418 meninge Anatomy 0.000 claims description 4
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 4
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000000649 small cell carcinoma Diseases 0.000 claims description 4
- 108010027164 Amanitins Proteins 0.000 claims description 3
- 206010065869 Astrocytoma, low grade Diseases 0.000 claims description 3
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims description 3
- 208000021994 Diffuse astrocytoma Diseases 0.000 claims description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 3
- 201000005409 Gliomatosis cerebri Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 201000007286 Pilocytic astrocytoma Diseases 0.000 claims description 3
- 201000007288 Pleomorphic xanthoastrocytoma Diseases 0.000 claims description 3
- 208000001662 Subependymal Glioma Diseases 0.000 claims description 3
- CIORWBWIBBPXCG-JZTFPUPKSA-N amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims description 3
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 3
- 208000014534 anaplastic ependymoma Diseases 0.000 claims description 3
- 230000003140 astrocytic effect Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 201000001169 fibrillary astrocytoma Diseases 0.000 claims description 3
- 201000011610 giant cell glioblastoma Diseases 0.000 claims description 3
- 208000002409 gliosarcoma Diseases 0.000 claims description 3
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 201000007344 pilomyxoid astrocytoma Diseases 0.000 claims description 3
- 201000004059 subependymal giant cell astrocytoma Diseases 0.000 claims description 3
- 208000030819 subependymoma Diseases 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 206010014968 Ependymoma malignant Diseases 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 102000009572 RNA Polymerase II Human genes 0.000 claims description 2
- 108010009460 RNA Polymerase II Proteins 0.000 claims description 2
- 102000014450 RNA Polymerase III Human genes 0.000 claims description 2
- 108010078067 RNA Polymerase III Proteins 0.000 claims description 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 2
- 206010041329 Somatostatinoma Diseases 0.000 claims description 2
- 208000009311 VIPoma Diseases 0.000 claims description 2
- 208000006336 acinar cell carcinoma Diseases 0.000 claims description 2
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 108010080146 androgen receptors Proteins 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 230000032823 cell division Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229960003649 eribulin Drugs 0.000 claims description 2
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 201000000052 gastrinoma Diseases 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 229960000908 idarubicin Drugs 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 2
- 206010022498 insulinoma Diseases 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 2
- 201000002529 islet cell tumor Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000009546 lung large cell carcinoma Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 230000007480 spreading Effects 0.000 claims description 2
- 238000003892 spreading Methods 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 229930184737 tubulysin Natural products 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 34
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 9
- SLURUCSFDHKXFR-WWMWMSKMSA-N (7s,9s)-7-[[(1s,3r,4as,9s,9ar,10as)-9-methoxy-1-methyl-3,4,4a,6,7,9,9a,10a-octahydro-1h-pyrano[1,2][1,3]oxazolo[3,4-b][1,4]oxazin-3-yl]oxy]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O=C1C2=CC=CC(OC)=C2C(=O)C(C(O)=C23)=C1C(O)=C3C[C@@](O)(C(=O)CO)C[C@@H]2O[C@H]1C[C@@H]2N3CCO[C@H](OC)[C@H]3O[C@@H]2[C@H](C)O1 SLURUCSFDHKXFR-WWMWMSKMSA-N 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 127
- 125000005647 linker group Chemical group 0.000 description 57
- 239000000523 sample Substances 0.000 description 43
- 235000001014 amino acid Nutrition 0.000 description 22
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 19
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 18
- 229940079593 drug Drugs 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 238000011534 incubation Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000002147 killing effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000000562 conjugate Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010068601 Glioneuronal tumour Diseases 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 241000283726 Bison Species 0.000 description 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000006050 Hemangiopericytoma Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 206010024612 Lipoma Diseases 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960000958 deferoxamine Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 239000008344 egg yolk phospholipid Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 108010059115 integrin alpha11beta1 Proteins 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000002500 microbody Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000001370 static light scattering Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 238000013298 xenograft nude mouse model Methods 0.000 description 2
- GKNPGQMJNWIEOE-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 3-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]propanoate Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1OC(=O)CCOCCOCCNC(=O)CCN1C(=O)C=CC1=O GKNPGQMJNWIEOE-UHFFFAOYSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- SXJJSALQDJZYKA-UHFFFAOYSA-N (2,5-dioxocyclopentyl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)C1OC(=O)CCSSC1=CC=CC=N1 SXJJSALQDJZYKA-UHFFFAOYSA-N 0.000 description 1
- VEGGTWZUZGZKHY-GJZGRUSLSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)-n-[4-(hydroxymethyl)phenyl]pentanamide Chemical compound NC(=O)NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)NC1=CC=C(CO)C=C1 VEGGTWZUZGZKHY-GJZGRUSLSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- DALMAZHDNFCDRP-VMPREFPWSA-N 9h-fluoren-9-ylmethyl n-[(2s)-1-[[(2s)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound O=C([C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)NC1=CC=C(CO)C=C1 DALMAZHDNFCDRP-VMPREFPWSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101800002638 Alpha-amanitin Proteins 0.000 description 1
- 208000013842 Anaplastic ganglioglioma Diseases 0.000 description 1
- 206010073127 Anaplastic meningioma Diseases 0.000 description 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 206010073129 Angiocentric glioma Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 208000037356 Atypical papilloma of choroid plexus Diseases 0.000 description 1
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 201000002844 Cerebellar liponeurocytoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000004378 Choroid plexus papilloma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000002847 Cowden syndrome Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229940121863 DNA inhibitor Drugs 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 230000010777 Disulfide Reduction Effects 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 201000004066 Ganglioglioma Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010060980 Granular cell tumour Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101001078149 Homo sapiens Integrin alpha-10 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102100025320 Integrin alpha-11 Human genes 0.000 description 1
- 101710123196 Integrin alpha-11 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000014503 Medulloblastoma with extensive nodularity Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 208000008846 Neurocytoma Diseases 0.000 description 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010048757 Oncocytoma Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 208000002063 Oxyphilic Adenoma Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000037064 Papilloma of choroid plexus Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 201000008789 Perineurioma Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000021308 Pituicytoma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 229940122277 RNA polymerase inhibitor Drugs 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- KVDVZTLIGXDKKC-BHWLZUDQSA-N [4-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound O=C([C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C)NC(C=C1)=CC=C1COC(=O)OC1=CC=C([N+]([O-])=O)C=C1 KVDVZTLIGXDKKC-BHWLZUDQSA-N 0.000 description 1
- USMYACISHVPTHK-PXLJZGITSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound O=C([C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)NC(C=C1)=CC=C1COC(=O)OC1=CC=C([N+]([O-])=O)C=C1 USMYACISHVPTHK-PXLJZGITSA-N 0.000 description 1
- HYSPJPGXSALJRR-DHIFEGFHSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(COC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O HYSPJPGXSALJRR-DHIFEGFHSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000004007 alpha amanitin Substances 0.000 description 1
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 1
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000013938 anaplastic oligoastrocytoma Diseases 0.000 description 1
- 208000009887 angiolipoma Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- 201000007360 atypical choroid plexus papilloma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000010702 central neurocytoma Diseases 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000013940 chordoid glioma of the third ventricle Diseases 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 208000006571 choroid plexus carcinoma Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000013757 desmoplastic infantile astrocytoma/ganglioglioma Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000004110 diffuse meningeal melanocytosis Diseases 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000004428 dysembryoplastic neuroepithelial tumor Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000014487 extraventricular neurocytoma Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 201000005649 gangliocytoma Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000017750 granulocytic sarcoma Diseases 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 208000027833 hibernoma Diseases 0.000 description 1
- 239000013628 high molecular weight specie Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000002865 local sequence alignment Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000009169 meningeal melanomatosis Diseases 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 206010073131 oligoastrocytoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 229940045795 other cytotoxic antibiotic in ATC Drugs 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 238000012831 peritoneal equilibrium test Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000004119 pineal parenchymal tumor of intermediate differentiation Diseases 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 206010035059 pineocytoma Diseases 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000012877 positron emission topography Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960005502 α-amanitin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to an integrin alphalO antibody drug conjugate and medical uses thereof.
- ADCs Antibodydrug conjugates
- tumour-selective drug delivery that may improve efficacy and reduce off-target toxicity [1]
- the ADC approach builds on a potent cytotoxic agent, a so called “payload”, conjugated to a tumour-targeting antibody.
- payload conjugated to a tumour-targeting antibody.
- the majority of ADCs follow a similar mode of action that involves internalization and subsequent payload release. This typically kills the target cell, and sometimes also nearby cells, which is referred to as the bystander effect.
- Integrin alphalO (gene name ITGA10) is a cell surface protein that belongs to the collagen-binding integrin subfamily, which consists of integrin alphalbetal, alpha2beta1, alpha10beta1 , and alpha11beta1 [3], Sequence analysis shows that the integrin alphalO subunit has the highest identity with integrin alpha 11 (43%) and an identity of 33 and 31% with integrin alphal and alpha2, respectively.
- Integrin alpha10beta1 is normally expressed on chondrocytes in articular cartilage, in the vertebral column, in trachea and in the cartilage supporting the bronchi and on some cells in specialised fibrous tissues such as periosteum and perichondrium that likely represent mesenchymal stem cells [3-7], However, integrin alphal Obetal is highly expressed in various aggressive cancers such as triple negative breast cancer, glioblastoma, prostate cancer, pancreatic cancer and lung cancer [8,9] (WO 2020/212416). Expression of integrin alpha10beta1 is associated with metastasis and increased tumour aggressiveness (WO 2020/212416).
- the present disclosure relates to an antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO, wherein the antibody or antigen-binding fragment comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO:
- a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7; e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ ID NO: 9.
- Another aspect of the present disclosure provides a polynucleotide encoding an antibody or antigen-binding fragment thereof according to the present disclosure or a component polypeptide chain thereof.
- Another aspect of the present disclosure provides a vector comprising a polynucleotide disclosed herein.
- Another aspect of the present disclosure provides a recombinant host cell comprising a polynucleotide disclosed herein.
- Another aspect of the present disclosure provides a method for producing an antibody or antigen-binding fragment thereof according to the present disclosure, the method comprising culturing a host cell comprising the polynucleotide or the vector according to the present disclosure, under conditions which permit expression of the encoded antibody or antigen-binding fragment thereof.
- Another aspect of the present disclosure provides for an in vitro method for the detection of cells expressing integrin alpha10beta1 in a subject, the method comprising: a) providing a sample of cells from a subject to be tested, such as biopsy tissue or blood sample; b) optionally, extracting and/or purifying the cells present in the sample; c) contacting an antibody or antigen-binding fragment thereof disclosed herein with cells present in the sample; d) determining whether the antibody or antigen-binding fragment thereof binds to the cells wherein the binding of the antibody or antigen-binding fragment thereof to the cells is indicative of the presence of a disease or disorder associated with cells expression integrin alphalO in the tissue of a subject.
- Another aspect of the present disclosure provides for an in vitro method for identifying a patient with a disease or disorder associated with cells expressing integrin alphalO who would benefit from treatment with an antibody or antigen-binding fragment thereof according to the present disclosure, the method comprising: a) providing a sample, such as biopsy tissue or blood sample from a patient to be tested; b) optionally, extracting and/or purifying the cells present in the sample; c) contacting an antibody or antigen-binding fragment thereof according to the present disclosure with the sample; d) determining whether the antibody or antigen-binding fragment thereof binds to an integrin alphalO subunit in the sample, wherein the binding of the antibody or antigen-binding fragment thereof to an integrin alphal 0 subunit is indicative of a patient who would benefit from treatment with an antibody or antigen-binding fragment thereof according to the present disclosure.
- Another aspect of the present disclosure provides for an in vitro method the detection of cells expressing integrin alphalO, the method comprising: a) contacting an antibody or antigen-binding fragment thereof according to the present disclosure with cells to be analysed for their expression of integrin alphalO; b) determining whether the antibody or antigen-binding fragment thereof binds to the cells wherein the binding of the antibody or antigen-binding fragment thereof to the cells is indicative of the presence of a disease or disorder associated with cells expression integrin alphalO in the tissue of a subject.
- Another aspect of the present disclosure provides for in vivo imaging the expression of the integrin alpha10beta1 in a mammal, the method comprising the steps of a) Providing a mammal, b) Providing an antibody or antigen-binding fragment thereof according to the present disclosure, c) administering the antibody or antigen-binding fragment thereof according to the present disclosure to the mammal so as to allow the antibody or a fragment thereof to bind to an extracellular domain of integrin alphal Obetal of cells in said mammal, d) optionally adding a second labelled antibody or a fragment thereof to the sample, wherein the second antibody or a fragment thereof binds to the antibody or a fragment thereof in c), e) detecting the antibody or antigen-binding fragment thereof according to the present disclosure of said cells in c), or optionally detecting the second labelled antibody or a fragment thereof in d) bound to the antibody or a fragment thereof, and f) creating an image of the detected antibody or a fragment thereof,
- the present disclosure provides for an antibody-drug conjugate directed against integrin alphalO comprising: a) an antibody or antigen-binding fragment thereof according to the present disclosure, b) an active agent, and c) optionally, a linker which links a) to b).
- the present disclosure provides a pharmaceutical composition comprising: the antibody or antigen-binding fragment thereof or the antibody-drug conjugate according to the present disclosure, and a pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.
- the present disclosure provides a method for delivery of an active agent to a cell expressing alpha10beta1 comprising administering to said cell the antibody-drug conjugate or the pharmaceutical composition according to the present disclosure, such that the active agent is delivered to said cell.
- the present disclosure provides for the antibody-drug conjugate as described herein, for use as a medicament.
- the present disclosure provides for the antibody-drug conjugate as described herein, for use in treating a patient with a disease or disorder associated with cells expressing integrin alphalO.
- the present disclosure provides for the antibody-drug conjugate as described herein, for use in the treatment of a neoplastic disease or disorder.
- the present disclosure provides a method for treatment of a disease characterized by expression of integrin alpha10beta1 in a subject, comprising administering to the subject the antibody-drug conjugate according to or the pharmaceutical composition according to the present disclosure.
- the present disclosure provides a use of the antibody-drug conjugate or the pharmaceutical composition according to the present disclosure for treatment of a disease.
- the present disclosure provides a kit comprising the antibody-drug conjugate or the pharmaceutical composition according to the present disclosure optionally further comprising means for administering the antibody-drug conjugate to a subject and/or instructions for use.
- Figure 1 bis-mPEG-Glu-(Val-cit-PAB-DMEDA-PNU159682)-6’-amino-p- cyclodextrin.
- the structure shows the conjugation technology, the linker and payload used in the antibody drug conjugates of the present disclosure. The structure is described more in detail in the section “Antibody-drug conjugate” herein.
- the curvy line indicates the attachment with an antibody of the present disclosure.
- FIG. 2 Internalization of five lead humanized antibody variants. Internalization of five antibody leads (Th-Ab9, Th-Ab11, Th-Ab12, Th-Ab14 and Th-Ab15) as well as a chimeric antibody (Th-AbO) and the mouse antibody (TM-Ab) was performed in C2C12alpha10 cells. The figure shows the percentage of antibody internalization after 4 hours incubation at 37 °C.
- Figure 3 Binding specificity and affinity of Th-Ab12-ADC to integrin alphalO.
- Binding specificity of Th-Ab12-ADC and the isotype control ADC (Ctrl-ADC) to C2C12alpha10 and C2C12alpha11 cells were investigated by flow cytometry (A). Binding affinity to C2C12alpha10 cells (B), triple negative breast cancer cell lines BT549 (C) and Hs578T (D), and glioblastoma cell lines U3046MG (E) and U3054MG
- FIG. 4 In vitro cytotoxicity of Th-Ab12-ADC. Cytotoxicity of Th-Ab12-ADC in comparison with Ctrl-ADC and payload only (PNll-159682) was studied in C2C12alpha10 cells (A), C2C12alpha11 cells in monolayer culture (B), triple negative breast cancer cell lines BT549 (C) and Hs578T (D) cultured as sphere, glioblastoma cell lines U3046MG (E) and U3054MG (F) cultured as sphere, rhabdoid tumour A204
- G cultured as monolayer
- osteosarcoma SJSA-1 H cultured as sphere.
- the cells were treated at the indicated concentrations for 5 days (C2C12alpha10, C2C12alpha11, A204, SJSA-1 cells) or 10 days (breast cancer and glioblastoma cells).
- the level of cytotoxicity was measured by WST-1 assay.
- FIG. 5 Internalization of Th-Ab12-ADC. Internalization of Th-Ab12-ADC and unconjugated antibody Th-Ab12 was performed in C2C12alpha10, triple negative breast cancer cells (BT549 and Hs578T), and glioblastoma cells (U3054MG and U3046MG). The figure shows the percentage of internalization after 90 min and after 4 hours of incubation at 37°C, compared to internalization at 4°C.
- FIG. 6 Effect of Th-Ab12-ADC on cell cycle distribution.
- C2C12alpha10 cells were treated with Th-Ab12-ADC or Ctrl-ADC at 0.02 nM for 5 days and the distribution (%) of the four indicated cell cycle stages was analysed using propidium iodide staining and flow cytometry.
- FIG. 8 In vivo efficacy of Th-Ab12-ADC.
- Figures A and C show that Th-Ab12-ADC reduced tumour growth compared to Ctrl-ADC and PBS, measured as reduction of tumour volume, measured by calliper.
- Figures B and D show that neither of the treatments had a negative effect on body weight.
- C2C12a10 cells were incubated with primary antibody against integrin a10 (Th-Ab12 or Tm-Ab) at a concentration of 10 pg/ml. After 30 min incubation with primary antibody, cells were washed twice with FACS buffer. Secondary antibody was then added according to Table 3 and incubated for 30 min. After incubation cells were washed twice with FACS buffer. Finally, a third antibody was added to samples 4 and 5 for the last incubation according to Table 3.
- FIGS A and B show that in C2C12a10 cells, when Th-Ab12 antibody was incubated first (sample 4; 4 on X-axis), Th-Ab12 showed the same binding degree as the single staining (sample 2; 2 on X-axis) while Tm-Ab did not show any binding (sample 4; 4 on X-axis).
- Tm-Ab was incubated first (sample 5; 5 on X-axis)
- addition of Th-Ab12 caused the binding signal for Tm-Ab to decrease of 20% and Th-Ab12 bound to 40% (Fig. 9B).
- an antibody includes a plurality of such antibodies.
- an anti-integrin alphalO antibody can also refer to “Anti-integrin alphalO antibodies”, as for example the antibody variants described in Examples 1 to 8.
- “Integrin alphalO” or “Integrin alphalO subunit” or “Integrin alphalO polypeptide” as used herein refers to the alphalO subunit of the heterodimeric protein integrin alpha10beta1. This denotation does not exclude the presence of the betal subunit bound to the alphalO subunit thus forming the integrin alpha10beta1 heterodimer. “Alpha” and “a”, as well as “alphalO” and “alphalO” are equivalent terms. “Integrin alphalO” as used herein may also refer to the polynucleotide transcript encoding the
- SUBSTITUTE SHEET (RULE 26) alphalO subunit of the heterodimeric protein integrin alpha10beta1, and fragments thereof.
- Anti-integrin alphalO antibody or “Integrin alphalO antibody” or “Anti-integrin alphalO subunit antibody” as used herein refers to an antibody capable of recognizing and binding to at least the alphalO integrin of the heterodimeric protein integrin alpha10beta1. These antibodies may be antibodies that recognize an epitope of the heterodimeric protein integrin alpha10beta1 , wherein the epitope comprises amino acid residues of both the alphalO and the betal integrin polypeptides.
- the antibody or antigen-binding fragment of the invention/disclosure can be referred to as “the polypeptide of the invention/disclosure” or “the antibody polypeptide, or antigen-binding fragment thereof”, since an antibody and fragments thereof are polypeptides.
- an antibody or an antigen-binding fragment thereof includes substantially intact antibodies as well as fragments and derivatives of antibodies.
- An intact antibody can be regarded as an antibody comprising variable light regions, variable heavy regions, constant light regions and constant heavy regions. It further includes chimeric antibodies, humanized antibodies, isolated human antibodies, single chain antibodies, bispecific antibodies, antibody heavy chains, antibody light chains, homodimers and heterodimers of antibody heavy and/or light chains, and antigenbinding fragments and derivatives of the same.
- Suitable antigen-binding fragments and derivatives include, but are not necessarily limited to, Fv fragments (e.g. single chain Fv and disulphide-bonded Fv), Fab-like fragments (e.g.
- Fab fragments, Fab’ fragments and F(ab)2 fragments single variable domains (e.g. VH and VL domains) and domain antibodies (dAbs, including single and dual formats [i.e. dAb-linker-dAb]).
- dAbs including single and dual formats [i.e. dAb-linker-dAb]).
- the potential advantages of using antibody fragments, rather than whole antibodies, are several-fold.
- the smaller size of the fragments may lead to improved pharmacological properties, such as better penetration of solid tissue.
- antigen-binding fragments such as Fab, Fv, ScFv and dAb antibody fragments can be expressed in and secreted from E. coli, thus allowing the facile production of large amounts of the said fragments.
- the term the “antibody” or “antigen-binding fragment of the invention/disclosure” is also intended to encompass antibody mimics (for example, non-antibody scaffold structures that have a high degree of stability yet allow variability to be introduced at certain positions).
- antibody mimics for example, non-antibody scaffold structures that have a high degree of stability yet allow variability to be introduced at certain positions.
- Exemplary antibody mimics include: affibodies (also called Trinectins; Nygren, 2008, FEBS J, 275, 2668-2676); CTLDs (also called Tetranectins; Innovations Pharmac. Technol.
- adnectins also called monobodies; Meth. Mol. Biol., 352 (2007), 95-109); anticalins (Drug Discovery Today (2005), 10, 23-33); DARPins (ankyrins; Nat. Biotechnol. (2004), 22, 575-582); avimers (Nat. Biotechnol. (2005), 23, 1556-1561); microbodies (FEBS J, (2007), 274, 86-95); peptide aptamers (Expert.
- amino acid as used herein includes the standard twenty genetically- encoded amino acids and their corresponding stereoisomers in the ‘D’ form (as compared to the natural 1’ form), omega-amino acids and other naturally-occurring amino acids, unconventional amino acids (e.g. a,a-disubstituted amino acids, N-alkyl amino acids, etc.) and chemically derivatised amino acids as described herein.
- unconventional amino acids e.g. a,a-disubstituted amino acids, N-alkyl amino acids, etc.
- amino acid when an amino acid is being specifically enumerated, such as “alanine” or “Ala” or “A”, the term refers to both L -alanine and D -alanine unless explicitly stated otherwise.
- polypeptides the antibody or antigen-binding fragment thereof
- Other unconventional amino acids may also be suitable components for polypeptides (the antibody or antigen-binding fragment thereof) of the present disclosure, as long as the desired functional property is retained by the antibody or antigen-binding fragment.
- amino acid sequences shown each encoded amino acid residue, where appropriate, is represented by a single letter designation, corresponding to the trivial name of the conventional amino acid.
- expression vector refers to a DNA construct containing a DNA sequence that is operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host.
- control sequences may, e.g., include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites and
- SUBSTITUTE SHEET (RULE 26) sequences which control termination of transcription and translation.
- the vector may, e.g., be a plasmid, a phage or simply a potential genomic insert. Once transformed into a suitable host, the vector may, e.g., replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself.
- Expression vectors are designed, for example, as described in Li et al. (Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells, Mol Biol Rep. 2018 Dec;45(6):2907-2912.)
- Subject denotes a mammal, such as a rodent, a feline, a canine, an equine and a primate.
- a subject according to the disclosure is a human.
- sample encompasses any subject and a variety of sample types obtained from any subject.
- samples useful in the disclosed methods include but are not limited to a subject, a liquid tissue sample such as blood, or a solid tissue sample such as biopsy material or tissue cultures or cells derived there from and the progeny thereof.
- biological samples include cells obtained from a tissue sample collected from a subject.
- samples encompass clinical samples, cells in culture, cell supernatants, cell lysates, and tissue samples, e.g. tissue samples from breast tissue, lung tissue, prostate tissue, pancreatic tissue, bone tissue, cartilage tissue, fat tissue, muscle tissue and connective tissue.
- a “cancer” as used herein refers to any malignant and/or invasive growth or tumor caused by abnormal cell growth.
- cancer refers to tumors named for the type of cells that form them.
- a cancer or tumor comprise of tumor cells or cancer cells.
- a cancer or tumor comprises also the cancer or tumor microenvironment, which can also comprise MSCs, fibroblasts, endothelial cells, pericytes, adipocytes, immune cells, tumor associated macrophages TAMs.
- Part of a cancer or tumor might be stroma cells, for example connective tissue cells such as fibroblasts. Examples of solid tumors include but are not limited to sarcomas and carcinomas.
- cancer includes but is not limited to a primary cancer that originates at a specific site in the body, a metastatic cancer that has spread from the place in which it started to other parts of the body, a recurrence from the original primary cancer after remission, and a second primary cancer that is a new primary cancer in a person with a history of previous cancer of different type from latter one. Cancer, tumor, neoplasm are used herein as synonyms.
- SUBSTITUTE SHEET (RULE 26) “Detection”, “detect”, “detecting” as used herein includes qualitative and/or quantitative detection (measuring levels) with or without reference to a control, and further refers to the identification of the presence, absence or quantity of a given target, specifically the target of an integrin alphalO subunit.
- disorder associated with cells expressing integrin alpha10beta1 we include such diseases or disorders wherein the pathological cells which are responsible, directly or indirectly, for the disorder express integrin alpha10beta1 on the cell surface.
- the cells expressing integrin alpha10beta1 may be immune cells, cells of the connective tissue such as fibroblasts or neoplastic cells (cancer cells), e.g. tumor cells, per se.
- cancer cells e.g. tumor cells
- progenitor cells which are responsible, directly or indirectly, for the development of a neoplastic disease or disorder in an individual. Examples of CSCs are disclosed in Visvader & Lindeman, 2008, Nat Rev Cancer 8:755-768, the disclosures of which are incorporated herein by reference.
- the cells expressing integrin alpha10beta1 may be associated indirectly with the neoplastic disease or disorder, for example, they may mediate cellular processes required for the cells to survive.
- the present disclosure relates to an antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO, wherein the antibody or antigen-binding fragment comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO: 1 ; b) a CDR-L2 comprising or consisting of an amino acid sequence of SEQ ID NO: 2; and c) a CDR-L3 comprising or consisting of an amino acid sequence of SEQ ID NO:
- a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7;
- SUBSTITUTE SHEET (RULE 26) e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ ID NO: 9.
- the present disclosure relates to an antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO, wherein the antibody or antigen-binding fragment comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO: 1 ; b) a CDR-L2 comprising or consisting of an amino acid sequence of SEQ ID NO: 2; and c) a CDR-L3 comprising or consisting of an amino acid sequence of SEQ ID NO: 3; and a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7; e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ ID NO
- the antibody or antigen-binding fragment of the disclosure has specificity for the alphal 0 subunit in the integrin alpha10beta1.
- specificity we mean that the antibody or antigen-binding fragment is capable of binding to integrin alpha10beta1 in vivo, i.e., under the physiological conditions in which integrin alphal Obetal exists within the human body.
- the antibody or antigen-binding fragment does not bind or has only minor binding to any other protein in vivo.
- it is meant that the antibody or antigen-binding fragment is capable of binding to integrin alphal Obetal ex vivo or in vitro.
- binding specificity may be determined by methods well known in the art, such as ELISA, immunohistochemistry, immunoprecipitation, Western blots and flow cytometry using transfected cells expressing integrin alphal Obetal .
- the antibody or antigen-binding fragment is capable of binding to integrin alpha10beta1 in vivo,
- SUBSTITUTE SHEET (RULE 26) antibody or antigen-binding fragment is capable of binding selectively to integrin alpha10beta1 , i.e., it binds at least 10-fold more strongly to integrin alpha10beta1 than to any other proteins.
- the antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO: 12 or a sequence having at least 85% sequence identity to any of SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO:12, such as at least 95%, such as 98% or 99% sequence identity to any of SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO:12; and/or b) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO: 19 or a sequence having at least 85% sequence identity to any of SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:
- the antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12 and an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16; or b) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12 and an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 15; or c) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 11 and an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16; or d) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 11 and an immunoglobulin
- SUBSTITUTE SHEET (RULE 26) heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 17; or e) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12 and an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 17.
- the antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin light chain variable region comprising CDR-L1 of SEQ ID NOU, CDR-L2 of SEQ ID NO:2 and CDR-L3 of SEQ ID NO:3; and b) an immunoglobulin heavy chain variable region comprising i. CDR-H1 of SEQ ID NO:4, CDR-H2 of SEQ ID NO:8 and CDR-H3 of SEQ ID NO:9, or ii. CDR-H1 of SEQ ID NO:5, CDR-H2 of SEQ ID NO:8 and CDR-H3 of SEQ ID NO:9.
- the antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12; and/or b) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16.
- the antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO: 1; b) a CDR-L2 comprising or consisting of an amino acid sequence of SEQ ID NO: 2; and c) a CDR-L3 comprising or consisting of an amino acid sequence of SEQ ID NO: 3; and/or a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence of SEQ ID NO: 4;
- SUBSTITUTE SHEET (RULE 26) e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ ID NO: 9.
- the antibody or antigen-binding fragment thereof comprises an IgG light chain constant region and an IgG heavy chain constant region.
- the antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin light chain constant region comprising or consisting of the amino acid sequence of SEQ ID NO: 20; and/or b) an immunoglobulin heavy chain constant region comprising or consisting of the amino acid sequence of SEQ ID NO: 21 .
- the antibody or antigen-binding fragment thereof with binding specificity for the integrin alphalO polypeptide which is a part of an integrin alpha10beta1 heterodimer.
- the antibody or antigen-binding fragment thereof with binding specificity for the integrin alpha10beta1 which is human integrin alpha10beta1.
- the antibody or antigen-binding fragment thereof with binding specificity for the integrin alpha10beta1 which is expressed on the surface of a cell is expressed on the surface of a cell.
- the antibody or antigen-binding fragment thereof binds to the extracellular l-domain of the integrin alphalO subunit.
- the antibody or antigen-binding fragment thereof with binding specificity for the integrin alpha10beta1 is selected from a mouse antibody, a chimeric antibody, a human antibody, a humanised antibody, a humanised antigen-binding fragment, a Fab fragment, a Fab’ fragment, an F(ab’)2 fragment, an Fv, a single chain antibody (SCA) such as an scFv, a disulphide-bonded Fv, the variable portion of the heavy and/or light chains thereof, and a Fab miniantibody.
- SCA single chain antibody
- the antibody or antigen-binding fragment thereof with binding specificity for the integrin alpha10beta1 is a monoclonal antibody or antigen-binding fragment thereof.
- the antibody or antigen-binding fragment thereof with binding specificity for the integrin alpha10beta1 is a humanised or fully human monoclonal antibody or antigen-binding fragment thereof.
- the antibody or antigen-binding fragment thereof with binding specificity for the integrin alpha10beta1 is a recombinant antibody or antigen-binding fragment thereof.
- the antibody or antigen-binding fragment of the invention comprises or consists of an antibody mimic selected from the group comprising or consisting of affibodies, tetranectins (CTLDs), adnectins (monobodies), anticalins, DARPins (ankyrins), avimers, iMabs, microbodies, peptide aptamers, Kunitz domains and affilins.
- CTLDs tetranectins
- adnectins monobodies
- anticalins DARPins (ankyrins)
- avimers iMabs, microbodies, peptide aptamers, Kunitz domains and affilins.
- the invention also encompasses modified versions of antibodies and antigen-binding fragments thereof, whether existing now or in the future, e.g., modified by the covalent attachment of polyethylene glycol or another suitable polymer.
- the antibody or antigen-binding fragment thereof with binding specificity for the integrin alpha10beta1 is conjugated to an additional moiety.
- the additional moiety comprises a detectable moiety, such as a detectable moiety selected from the group consisting of a fluorophore, an enzyme and a radioactive tracer or radioisotope.
- a detectable moiety selected from the group consisting of a fluorophore, an enzyme and a radioactive tracer or radioisotope.
- the radioisotope is selected from the group consisting of 99mTc, 111 In, 67Ga, 68Ga, 72As, 89Zr, 1231 and 201TI.
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO comprises a pair of detectable and cytotoxic radioisotopes, such as 86Y/90Y or 1241/211 At.
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO comprises a radioisotope which is capable of simultaneously acting in a multi-modal manner as a detectable moiety and as a cytotoxic moiety.
- the detectable moiety comprises or consists of a paramagnetic isotope.
- the paramagnetic isotope is selected from the group consisting of 157Gd, 55Mn, 162Dy, 52Cr and 56Fe.
- the detectable moiety is detectable by an imaging technique such as SPECT, PET, MRI, optical or ultrasound imaging.
- the detectable moiety is joined to the antibody or antigen-binding fragment thereof indirectly, via a linking moiety.
- the linking moiety is a chelator.
- the chelator is selected from the group consisting of derivatives of 1 ,4, 7, 10-tetraazacyclododecane-1 , 4, 7, 10, tetraacetic acid (DOTA), deferoxamine (DFO), derivatives of diethylenetriaminepentaacetic avid (DTPA), derivatives of S-2-(4- lsothiocyanatobenzyl)-1 ,4,7-triazacyclononane-1 ,4,7-triacetic acid (NOTA) and derivatives of 1 ,4,8,11-tetraazacyclodocedan-1 , 4, 8, 11 -tetraacetic acid (TETA).
- DFA deferoxamine
- DTPA diethylenetriaminepentaacetic avid
- NOTA N-(4- lsothiocyanatobenzyl)-1 ,4,7-triazacyclononane-1 ,4,7-triacetic acid
- TETA tetraacetic acid
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO does not comprise a detectable moiety.
- Integrins are heterodimers consisting of an alpha and a beta polypeptide.
- the integrin alpha10beta1 heterodimer may be detected by integrin alphalO-specific antibodies and integrin alphalO binding peptides and proteins.
- the integrin alphalO polypeptide is a part of an integrin alpha10beta1 heterodimer.
- the integrin alphalO polypeptide is expressed on the surface of the cells.
- the integrin alpha10beta1 was originally identified as a collagen type II binding receptor on chondrocytes in 1998 (Camper et al., 1998). In vitro studies have demonstrated its binding to other collagen subtypes and to laminin (Lundgren-Akerlund Book chapter and Thoren et al). Immunohistochemical analysis during development and in adult tissues has demonstrated a restricted localization to cartilage-containing tissues and to some fibrous tissues (Camper et al. 1998, Camper et al., 2001). Knockout mice lacking the marker have disorganized growth plates, decreased collagen in the matrix and shorter long-bones, further supporting its cell structural importance (Bengtsson et al., 2005). The amino acid sequence, variants, isoforms and sequence annotations can be found in Uniprot accession no 075578 (ITA10_HUMAN).
- Integrin alpha10beta1 receptors transmit, upon binding to the extracellular ligand, intracellular signals that promote cell adhesion, migration, survival, proliferation, tumor growth and metastasis. Inhibition of the receptor thus impedes adhesion, migration, survival, proliferation, tumor growth and metastasis. This may be important for the treatment of many proliferative diseases such as cancer and inflammatory diseases.
- integrin alphalO is a naturally occurring variant of integrin alphalO polypeptide, an isoform of integrin alphalO polypeptide or a splice variant of an integrin alphalO polypeptide.
- Integrin alphalO can also be detected on nucleotide level by analyzing a sample for the presence of e.g. mRNA transcripts which upon translation generates an integrin alphalO antigen as defined herein above.
- the antibody of the present invention is defined by its characteristic complementaritydetermining region (CDR) sequences.
- CDR characteristic complementaritydetermining region
- the CDRs of the antibody of the present invention have been defined using definition according to Kabat.
- CDR-L1 , CDR-L2, CDR-L3, CDR-H1 , CDR-H2, CDR-H3) may be defined according to Kabat.
- CDRs of the antibody of the invention by other approaches, for example by definition of CDRs according to Chothia (Al-Lazikani et al., (1997) JMB 273,927-948), Martin (Enhanced Chotia), Gelfand or Honneger. Further approaches exist, such as the AbM definition (combination of Kabat definition and Chothia definition used by Oxford Molecular's AbM antibody modelling software) or the contact definition (based on analysis of crystal structures). See, e.g., Kabat et al. (Sequences of Proteins of Immunological Interest, 1987 and 1991, NIH, Bethesda, Md.), Lefranc et al.
- CDRs it can be beneficial to define the CDRs according to one numbering system, such as Kabat. Often, these CDR sequences are short (shorter than, for example, an approach combining numbering systems), thus providing the core sequences critical for binding. In other cases, it can be beneficial to use a combination of, for example, IMGT and Kabat CDR sequences.
- the disclosure relates to an antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO, wherein the antibody or antigen-binding fragment comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO: 1 ; b) a CDR-L2 comprising or consisting of an amino acid sequence of SEQ ID NO: 2; and c) a CDR-L3 comprising or consisting of an amino acid sequence of SEQ ID NO: 3; and/or a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7; e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ
- the antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO: 1 ; b) a CDR-L2 comprising or consisting of an amino acid sequence of SEQ ID NO: 2; and c) a CDR-L3 comprising or consisting of an amino acid sequence of SEQ ID NO: 3; and/or a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence of SEQ ID NO: 4;
- SUBSTITUTE SHEET (RULE 26) e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ ID NO: 9.
- the antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO: 1 ; b) a CDR-L2 comprising or consisting of an amino acid sequence of SEQ ID NO: 2; and c) a CDR-L3 comprising or consisting of an amino acid sequence of SEQ ID NO: 3; and/or a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence of SEQ ID NO: 5; e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ ID NO: 9.
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO comprises CDRs as described above (comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs 1 to 9), wherein any one of the amino acids of the CDRs has been altered for another amino acid, for example, with the proviso that no more than 2 amino acids have been so altered, such as 1 amino acid.
- the antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO:12 or a sequence having at least 85% sequence identity to any of SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO:12,
- SUBSTITUTE SHEET such as at least 95%, such as 98% or 99% sequence identity to any of SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO:12; and/or b) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO: 19 or a sequence having at least 85% sequence identity to any of SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19, such as at least 95%, such as 98% or 99% sequence identity to any of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19, such
- the antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12; and/or b) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16.
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO comprises a light chain variable region comprising or consisting of a) the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 12, for example at least 90%, 95%, 98% or 99% sequence identity; or b) an amino acid sequence selected from the group consisting of SEQ ID NO: 10 and SEQ ID NO:11 , or an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 10 and SEQ ID NO:11 , for example at least 90%, 95%, 98% or 99% sequence identity to any one of SEQ ID NO: 10 and SEQ ID NO:11.
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO comprises a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 12, for example at least 90%, 95%, 98% or 99% sequence identity.
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO comprises a heavy chain variable region comprising or consisting of a) the amino acid sequence of SEQ ID NO: 16; or an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 16 for example at least 90%, 95%, 98% or 99% sequence identity; or b) an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO: 19; or an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO: 19, for example at least 90%, 95%, 98% or 99% sequence identity to any one of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO:17
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO comprises a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16; or an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 16 for example at least 90%, 95%, 98% or 99% sequence identity.
- Percent identity can be determined by, for example, the LALIGN program at the Expasy facility site (http://www.ch.embnet.org/software/LALIGN_form.html) using as parameters the global alignment option, scoring matrix BLOSUM62, opening gap penalty -14, extending gap penalty -4.
- the percent sequence identity between two polypeptides, such as parts of an antibody may be determined using suitable computer programs, for example the GAP program of the University of Wisconsin Genetic Computing Group and it will be appreciated that percent identity is calculated in relation to polypeptides whose sequence has been aligned optimally.
- the alignment may alternatively be carried out using the Clustal W program.
- the parameters used may be as follows:
- the BESTFIT program may be used to determine local sequence alignments.
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO comprises a light chain variable region and/or a heavy variable chain region as described above, wherein any one of the amino acids of the framework region of the light chain variable region and/or a heavy variable chain region has been altered for another amino acid, with the proviso that no more than 5 amino acids have been so altered, such as 4 amino acids, no more than 3 amino acids, such as 2 amino acids or no more than 1 amino acid.
- variable light and variable heavy chains Combination of variable light and variable heavy chains
- the antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12; and/or b) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16.
- Another aspect of the disclosure relates to a polynucleotide encoding the antibody or antigen-binding fragment of the present disclosure, or a component polypeptide chain
- polynucleotide we include DNA (e.g. genomic DNA or complementary DNA) and mRNA molecules, which may be single- or double-stranded.
- the polynucleotide is an isolated polynucleotide.
- the polynucleotide is a cDNA molecule.
- polynucleotide may be codon- optimised for expression of the antibody or antigen-binding fragment in a particular host cell, e.g. for expression in human cells (for example, see Angov, 2011, Biotechnol. J. 6(6):650-659, the disclosures of which are incorporated herein by reference).
- the polynucleotide encoding the antibody or antigen-binding fragment of the disclosure is encoding an antibody light chain or variable region thereof.
- the polynucleotide encoding the antibody or antigen-binding fragment of the disclosure is encoding an antibody heavy chain or variable region thereof.
- the polynucleotide encoding the antibody or antigen-binding fragment of the disclosure is encoding an antibody comprising: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12; and/or b) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16.
- Another aspect of the disclosure relates to a vector comprising the polynucleotide according to another aspect of the disclosure.
- the vector is an expression vector.
- expression vector is defined herein as a DNA molecule, for example linear or circular, which comprises a polynucleotide encoding a polypeptide of the present
- SUBSTITUTE SHEET (RULE 26) invention (the antibody or antigen-binding fragment thereof) and is operably linked to additional nucleotides that provide for its expression.
- plasmid the expression vector
- vector vector
- Another aspect of the disclosure relates to a recombinant host cell comprising the polynucleotide according to another aspect of the disclosure or a vector according to another aspect of the disclosure.
- the recombinant host cell is a bacterial cell.
- the recombinant host cell is a yeast cell.
- the recombinant host cell is a mammalian cell.
- the recombinant host cell is a human cell.
- Another aspect of the disclosure relates to a method for producing the antibody or antigen-binding fragment of the another aspect of the invention, the method comprising culturing the host cell of another aspect of the disclosure comprising the polynucleotide of another aspect of the disclosure or the vector of the third aspect of the disclosure, under conditions which permit expression of the encoded antibody or antigen-binding fragment thereof.
- Another aspect of the disclosure provides for an in vitro method for the detection of cells expressing integrin alpha10beta1 in a subject, the method comprising: a) providing a sample of cells from a subject to be tested, such as biopsy tissue or blood sample; b) optionally, extracting and/or purifying the cells present in the sample; c) contacting the antibody or antigen-binding fragment of the present disclosure with cells present in the sample; d) determining whether the antibody or antigen-binding fragment thereof binds to the cells,
- SUBSTITUTE SHEET (RULE 26) wherein the binding of the antibody or antigen-binding fragment thereof to the cells is indicative of the presence of a disease or disorder associated with cells expression integrin alphalO in the tissue of a subject.
- Yet another aspect of the present disclosure provides for an in vitro method for identifying a patient with a disease or disorder associated with cells expressing integrin alphalO who would benefit from treatment with an antibody or antigen-binding fragment thereof according to the present disclosure, the method comprising: a) providing a sample, such as biopsy tissue or blood sample from a patient to be tested; b) optionally, extracting and/or purifying the cells present in the sample; c) contacting an antibody or antigen-binding fragment thereof according to the present disclosure with the sample; d) determining whether the antibody or antigen-binding fragment thereof binds to an integrin alphalO subunit in the sample, wherein the binding of the antibody or antigen-binding fragment thereof to an integrin alphalO subunit is indicative of a patient who would benefit from treatment with an antibody or antigen-binding fragment thereof according to the present disclosure.
- the antibody or antigen-binding fragment thereof according to the present disclosure can be used to detect an integrin alphalO subunit as found on the surface of cells, in particular cancer cells, expressing integrin alphalO as well as freely circulating in the blood of a patient.
- integrin alphalO can be released from the cell membrane, for example due to the action of proteases, and end up in blood (shedding of integrin alphalO subunit).
- the antibody or antigenbinding fragment thereof according to the present disclosure can be used to detect an integrin alphalO subunit directly in blood of a patient.
- the present disclosure provides for a method for the detection of cells expressing integrin alphalO, the method comprising: a) contacting an antibody or antigen-binding fragment thereof according to the present disclosure with cells to be analysed for their expression of integrin alphalO; b) determining whether the antibody or antigen-binding fragment thereof binds to the cells
- SUBSTITUTE SHEET (RULE 26) wherein the binding of the antibody or antigen-binding fragment thereof to the cells is indicative of the presence of a disease or disorder associated with cells expression integrin alphalO in the tissue of a subject.
- said method can be is an in vivo method or an in vitro method.
- the disclosure provides for a method for in vivo imaging the expression of the integrin alpha10beta1 in a mammal, the method comprising the steps of a) Providing a mammal, b) Providing an antibody or antigen-binding fragment thereof according to the present disclosure, c) administering the antibody or antigen-binding fragment thereof according to the present disclosure to the mammal so as to allow the antibody or a fragment thereof to bind to an extracellular domain of integrin alpha10beta1 of cells in said mammal, d) optionally adding a second labelled antibody or a fragment thereof to the sample, wherein the second antibody or a fragment thereof binds to the antibody or a fragment thereof in c), e) detecting the antibody or antigen-binding fragment thereof according to the present disclosure of said cells in c), or optionally detecting the second labelled antibody or a fragment thereof in d) bound to the antibody or a fragment thereof, and f) creating an image of the detected antibody or
- the antibody is covalently bound to a detectable moiety, such as a detectable moiety selected from the group consisting of a fluorophore, an enzyme, a radioactive tracer or a radioisotope.
- a detectable moiety selected from the group consisting of a fluorophore, an enzyme, a radioactive tracer or a radioisotope.
- the integrin alphalO antigen may also be detected by detecting a peptide, protein or polypeptide other than integrin alphalO polypeptide, wherein said other peptide, protein or polypeptide is capable of specifically binding to an integrin alphalO antigen.
- said peptide, protein or polypeptide is linked to an enzyme, a fluorophore or a radioactive tracer.
- the radioactive tracer may e.g. be selected from a positron emitter, or a gamma emitter. Conjugation of the antibody to a detectable moiety facilitates and improves detection
- SUBSTITUTE SHEET (RULE 26) said antibody, which in turn may facilitate detection of integrin alphalO-expressing cells in a sample and so the diagnosis of a cancer.
- the antibody of the present disclosure can be used to detect integrin alphalO on cells, in tissues, in blood of a sample obtained from a mammal, such as in vitro, or even in vivo and/or in situ by using in vivo antibody-based detection techniques described herein and/or known to the person of skill in art.
- the person of skill in the art is capable of selecting the standard laboratory equipment for detection of the integrin alphalO antibodies, depending on the situation and physical state of the sample.
- the person of skill in the art would conduct the detection step using flow cytometry such as Fluorescence-Activated Cell Sorting (FACS).
- flow cytometry such as Fluorescence-Activated Cell Sorting (FACS).
- Typical immunological methods well known in the art include but are not limited to western blot, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunohistochemistry (IHC), immunofluorescent assay (IF), fluorescence in situ hybridization (FISH).
- ELISA enzyme linked immunosorbent assay
- RIA radioimmunoassay
- IHC immunohistochemistry
- IF immunofluorescent assay
- FISH fluorescence in situ hybridization
- Detecting integrin alphalO can be achieved using methods well known in the art of detection and imaging, such as clinical imaging, such as conventional fluorescence microscopes, confocal microscope, 2-photon microscopes, stimulated emission depletion (STED) etc.
- clinical imaging such as conventional fluorescence microscopes, confocal microscope, 2-photon microscopes, stimulated emission depletion (STED) etc.
- the detectable moiety is selected from the group consisting of a fluorophore, an enzyme or a radioactive tracer.
- Typical methods for detection of cell surface antigens in vivo include but are not limited to fluorescence imaging, positron emission tomography, x- ray computed tomography (CT), magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI), ultrasound and single-photon emission computed tomography (SPECT).
- CT positron emission tomography
- MRI magnetic resonance imaging
- fMRI functional magnetic resonance imaging
- SPECT single-photon emission computed tomography
- cell surface antigens can be imaged in vivo using immunolabelling with a radioactive tracer bound to an antibody or other specifically binding protein.
- the antibodies used for in vivo imaging are antibody fragments such as Fab fragments, and single chain antibodies due to their smaller size and absence of effector function.
- An antibody-drug conjugate is formed by covalent biochemical conjugation of a monoclonal antibody with high toxic payload via a small molecular linker.
- ADC manufacturing is a multiple step process that can be divided into three distinct stages: cGMP production of the antibody, cGMP synthesis of the drug-linker complex, and conjugation to form an ADC.
- the conjugated antibodies subsequently undergo an extensive purification process.
- the present disclosure provides for an antibody-drug conjugate directed against integrin alphalO comprising: a) an antibody or antigen-binding fragment thereof as defined in the present disclosure, b) an active agent, and c) optionally, a linker which links a) to b).
- the antibody is attached to the linker through a conjugating unit.
- the antibody-drug conjugate of the present disclosure also comprises a functional unit, for example a unit that improved solubility of the antibodydrug conjugate.
- the antibody drug conjugate (ADC) of the present disclosure comprises an active agent, i.e. a drug, which can be delivered intracellularly to cells expressing integrin alpha10beta1.
- the active agent may e.g. be a therapeutic agent, a cytotoxic agent, a radioisotope or a detectable label. In a preferred embodiment the active agent is a therapeutic agent.
- said active agent is a therapeutic agent, a cytotoxic agent, a microtubule toxin or a transcription toxin.
- the active agent is a chemotherapeutic agent.
- Classes of chemotherapeutic agents include alkylating agents, anthracyclines, antimetabolites, anti-microtubule/anti-mitotic agents, histone deacetylase inhibitors, kinase inhibitors, dihydrofolate reductase inhibitors, peptide antibiotics, platinum-based antineoplastics, topoisomerase inhibitors and cytotoxic antibiotics.
- the active agent may be or comprise a radioisotope.
- the radioisotope may serve as a radiation emitter either for treatment of affected tissues or for diagnostic purposes.
- the radioisotope may consist of or comprise 60Co, 89Sr, 90Y, 99mTc, 1311, 137Cs, 153Sm, or 223Rd.
- the radioisotope may be in combination with a chelator such as DOTA or EDTA or others which are well known in the art.
- the active agent is a therapeutic agent.
- Classes of therapeutic agents include DNA crosslinking agents, DNA alkylating agents, DNA strand scission agents, anthracyclines, antimetabolites, anti-microtubule/anti-mitotic agents, histone deacetylase inhibitors, kinase inhibitors, metabolism inhibitors, peptide antibiotics, immune checkpoint inhibitors, platinum-based antineoplastics, topoisomerase inhibitors, DNA or RNA polymerase inhibitors, immunomodulators, nucleotide-based agents, and cytotoxic antibiotics.
- the active agent is a cytotoxic agent.
- the active agent is a therapeutic agent, such as a therapeutic agent selected from the group consisting of microtubule toxins, DNA toxins and transcription toxins.
- the active agent is a microtubule toxin, such as a microtubule toxin selected from the group consisting of Auristatin-based toxins, Maytansinoid-based toxins, Tubulysins-based toxins and Eribulin.
- the active agent is a transcription toxin, such as an RNA polymerase II and/or III inhibiting agent.
- the active agent is a therapeutic agent, such as a therapeutic agent selected from the group consisting of alkylating agents, anthracyclines, antimetabolites, anti-microtubule/anti-mitotic agents, histone deacetylase inhibitors, kinase inhibitors, peptide antibiotics, platinum-based antineoplastics, topoisomerase inhibitors and cytotoxic antibiotics.
- a therapeutic agent selected from the group consisting of alkylating agents, anthracyclines, antimetabolites, anti-microtubule/anti-mitotic agents, histone deacetylase inhibitors, kinase inhibitors, peptide antibiotics, platinum-based antineoplastics, topoisomerase inhibitors and cytotoxic antibiotics.
- the active agent is a transcription toxin selected from the group consisting of Doxorubicin, Doxorubicin derivatives and Amanitin.
- the active agent is an anthracycline, such as an anthracycline selected from Daunorubicin, doxorubicin, epirubicin, idarubicin, and 3'-deamino-3"-4'- anhydro-[2"(S)-methoxy-3"(R)-hydroxy-4''-morpholinyl]doxorubicin (PNll 159682).
- an anthracycline selected from Daunorubicin, doxorubicin, epirubicin, idarubicin, and 3'-deamino-3"-4'- anhydro-[2"(S)-methoxy-3"(R)-hydroxy-4''-morpholinyl]doxorubicin (PNll 159682).
- the active agent is 3'-deamino-3"-4'-anhydro-[2"(S)- methoxy-3"(R)-hydroxy-4"-morpholinyl]doxorubicin (PNU159682), which is represented in Formula X: attachment site to a linker.
- the active agent is a DNA- or RNA-polymerase inhibitor, such as a polymerase inhibitor selected from amanitin or alpha-amanitin or derivatives thereof, actinomycin D, and aphidicolin.
- the active agent is a nucleotide-based agent, such as an RNA- or DNA-oligonucleotide, such as a siRNA or a miRNA
- DAR drug-to-antibody ratio
- the DAR is between 1 and 10, such as between 2 and 8, for example between 3 and 6, such as 1, 2, 3 or 4.
- the DAR is 1 or 2.
- Linkers may e.g. be based on chemical motifs including disulfides, hydrazones or peptides (cleavable), or thioethers (non-cleavable), and control the distribution and delivery of the cytotoxic agent to the target cell. Cleavable and non- cleavable types of linkers have been proven to be safe in preclinical and clinical trials.
- the ADC as disclosed herein comprises a linker that links the antibody to the active agent.
- the antibody-drug conjugate comprises a linker selected from a cleavable and a non-cleavable linker.
- linker cleavable or non-cleavable
- cleavable linkers can e.g. be cleaved by enzymes in the target cell, leading to efficient intracellular release of the active agent, for example a cytotoxic agent.
- an ADC containing a non-cleavable linker has no mechanism for drug release, and must rely on mechanisms such as degradation of the targeting antibody, for drug release.
- the linker composition may influence critical factors such as solubility and pharmacokinetic properties of the ADC as a whole.
- drug release is crucial for obtaining a cellular effect.
- Drugs which are able to freely diffuse across cell membranes may escape from the targeted cell and, in a process called “bystander killing,” also attack neighbouring cells, such as cancer cells in the vicinity of the integrin alpha10beta1 expressing target cell.
- Cleavable groups include a disulfide bond, an amide bond, a substituted amide bond in the form of a peptide bond, a thioamide, bond, an ester bond, a thioester bond, a vicinal diol bond, or a hemiacetal.
- cleavable bonds may include enzymatically-cleavable bonds, such as peptide bonds (cleaved by peptidases), phosphate bonds (cleaved by phosphatases), nucleic acid bonds (cleaved by endonucleases), and sugar bonds (cleaved by glycosidases).
- the linker is a cleavable linker allowing for intracellular release of the active agent inside the target cells.
- linker from those routinely used for ADCs.
- linkers include but not limited to Val-Cit-PAB, Fmoc-Val-Cit-PAB, Fmoc-Val-Cit-PAB-PNP, MC-Val-Cit-PAB-PNP, Phe- Lys(Trt)-PAB, Fmoc-Phe-Lys(Trt)-PAB, Fmoc-Phe-Lys(Trt)-PAB-PNP, Ala-Ala-Asn- PAB TFA salt, Fmoc-Ala-Ala-Asn-PAB-PNP, Fmoc-Gly3-Val-Cit-PAB, Fmoc-Gly3-Val- Cit-PAB-PNP, SMCC, Py-ds-Prp-OSu, Py-ds-dmBut-OSu, Py-ds-dmBut-OSu, Py-ds-dmBut-
- the linker is an enzyme-cleavable linker, such as a cathepsin cleavable linker.
- the linker comprises a peptide linker.
- the choice of peptide sequence is critical to the success of the conjugate.
- the linker is stable to serum proteases, yet is cleaved by lysosomal enzymes in the target cell.
- the linker is an enzyme-cleavable peptide-containing linker, such as a cathepsin cleavable peptide-containing linker.
- Cathepsin can be one of several cathepsin types, being one of a group of lysosomal proteases.
- the linker comprises a dipeptide, such as Valine-Citrulline (Val- Cit) or Valine-Alanine (Val-Ala).
- the linker comprises the dipeptide Valine-Citrulline (Val-Cit, Formula V).
- Enzymatically cleavable linkers may include a “self-immolative molecule” also referred to as “self-immolative spacer” or “self-immolative linker” to spatially separate the drug from the site of enzymatic cleavage.
- a self-immolative spacer also referred to as “self-immolative spacer” or “self-immolative linker” to spatially separate the drug from the site of enzymatic cleavage.
- the direct attachment of a drug to a peptide linker can result in proteolytic release of an amino acid adduct of the drug, thereby impairing its activity.
- the use of a self-immolative spacer allows for the elimination of the fully active, chemically unmodified drug upon amide bond hydrolysis.
- the linker comprises one or more self-immolative molecules.
- self-immolative molecules include p-aminobenzylcarbamoyl (PAB) and N,N'-Dimethylethylenediamine (DMEDA).
- the linker comprises a dipeptide and p-aminobenzylcarbamoyl (PAB, Formula P).
- the linker comprises a N,N'-Dimethylethylenediamine (DMEDA, Formula D).
- DMEDA N,N'-Dimethylethylenediamine
- the linker comprises a dipeptide, such as Valine-Citrulline (Val-Cit) or Valine-Alanine (Val-Ala), and the self-immolative molecules p- aminobenzylcarbamoyl (PAB) and N,N'-Dimethylethylenediamine (DM EDA).
- a dipeptide such as Valine-Citrulline (Val-Cit) or Valine-Alanine (Val-Ala)
- PAB p- aminobenzylcarbamoyl
- DM EDA N,N'-Dimethylethylenediamine
- the linker comprises or consists of Val-Cit-PAB-DMEDA, as represented in Formula Y.
- the antibody-drug conjugate of one aspect of present disclosure further comprises a conjugating unit, such as a conjugating unit derived from reactive groups such as a functionalized benzoic acid, an activated carboxylic acid derivative, an amino group, a maleimide group or derivatives thereof, N-hydroxysuccinimide, bissulfones, azides and alkynes via click chemistry, reactive attachment groups directed to modified or unmodified protein-bound carbohydrate, peptide sequences that are required for enzymatic reactions, by reaction with the antibody or a chemically or enzymatically generated derivative thereof.
- a conjugating unit such as a conjugating unit derived from reactive groups such as a functionalized benzoic acid, an activated carboxylic acid derivative, an amino group, a maleimide group or derivatives thereof, N-hydroxysuccinimide, bissulfones, azides and alkynes via click chemistry, reactive attachment groups directed to modified or unmodified protein-bound carbohydrate, peptide sequences that are required for
- the conjugating unit is derived from a functionalized bis-sulfone group according to Formula C below:
- R and R’ are each independently selected form the group consisting of selected from the group consisting of Ci-Ce alkyl, a C3-C7 cycloalkyl, a C3-C7 heterocycloalkyl, phenyl, C5-C10 aryl, each of which may optionally be substituted by one or more selected from halogen, cyano, amino, Ci-Ce alkyl, Ci-Ce alkoxy, phenyl, and C5-C10 aryl.
- the antibody or antigen-binding fragment thereof with binding specificity for integrin alphalO disclosed herein may be conjugated to the conjugating unit via a number of inter-chain thiol bridging groups across both the light chain and heavy chain constant regions of the antibody, as well as inter-chain thiol bridging groups between the heavy chain constant regions of the antibody.
- the conjugating unit when the conjugating unit is derived from a functionalized bis- sulfone group, such as Fornula C or C’ or C”, the conjugation may occur by means of a disulfide reduction, such as by means of a reaction between one or more -SH groups of cysteines within the antibody or antigen-binding fragment thereof and the sulfone groups of the conjugating unit. Consequently, the SCh-PEGn-unit may by a leaving group which detaches from the conjugated ADC.
- a disulfide reduction such as by means of a reaction between one or more -SH groups of cysteines within the antibody or antigen-binding fragment thereof and the sulfone groups of the conjugating unit. Consequently, the SCh-PEGn-unit may by a leaving group which detaches from the conjugated ADC.
- the conjugating unit is derived from a functionalized bis-sulfone group according to formula C’ Formula C’ wherein * indicates an attachment site to a linker, and wherein n is an integer between 1 and 10.
- the conjugating unit is derived from a functionalized bis-sulfone group according to formula C”, also herein referred to as bis-mPEG.
- the conjugating unit conjugates the antibody against integrin alphalO of the present disclosure to the linker, which is attached to the active agent.
- the conjugating unit is derived from a functionalized bis-sulfone group such as any of Formula C, C’ or C”, and is functionalized with a glutamic acid.
- the conjugating unit is derived from a functionalized bis-sulfone group according to formula C”, also herein referred to as bison PEG , and functionalized with a glutamic acid to form a bis-mPEG-Glu, wherein the Glu is attached to the * in Formula C”.
- the antibody-drug conjugate of one aspect of present disclosure comprises a functional unit, such as a unit that improves solubility of the antibody-drug conjugate, such as a cyclodextrin or a PEG molecule.
- the functional unit comprises or consists of 6’-amino-p- cyclodextrin.
- the functional unit comprises or consists of a PEG molecule having a molecular weight of 10 kDa or below, such as 8 kDa, such as 5 kDa or below, such as 4.6 kDA, such as 4 kDa, such as 1 kDa, such as 0.6 kDA, such as 0.4 KDa, such as 0.2 kDA.
- the functional unit such as the unit that improves solubility of the antibody-drug conjugate comprises or consists of a PEG molecule consisting of 72 PEG units or less, such as 50 PEG units, such as 20 PEG units.
- the functional unit is attached to the conjugating unit.
- the functional unit is attached to the glutamic acid comprised in the conjugating unit.
- the functional unit is attached to the linker.
- the antibody-drug conjugate of the present disclosure comprises bis-mPEG-Glu-(Val-cit-PAB-DMEDA-PNU159682)-6’-amino-p-cyclodextrin, as represented in Formula A.
- the antibody-drug conjugate of the present disclosure comprises: a) the antibody or antigen-binding fragment thereof according to another aspect of the present disclosure, wherein the antibody or antigen-binding fragment thereof comprises
- a heavy chain variable region comprising a CDR-H1 consisting of any one of SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, a CDR-H2 consisting of SEQ ID NO:5 and a CDR-H3 consisting of SEQ ID NO:6;
- a conjugating unit such as a conjugating unit derived from a bis-sulfone group according to formula C” and functionalized with a glutamic acid (bis-mPEG- Glu);
- a linker comprising or consisting of Val-cit-PAB-DMEDA;
- a functional unit such as 6’-amino-p-cyclodextrin; and e) the active agent PNU159682.
- the antibody-drug conjugate comprises an antibody or antigenbinding fragment that comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO: 1 ; b) a CDR-L2 comprising or consisting of an amino acid sequence of SEQ ID NO: 2; and c) a CDR-L3 comprising or consisting of an amino acid sequence of SEQ ID NO: 3; and a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence of SEQ ID NO: 4; e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ ID NO: 9.
- the antibody-drug conjugate comprises an antibody or antigenbinding fragment that comprises: a light chain variable region comprising a) a CDR-L1 comprising or consisting of an amino acid sequence of SEQ ID NO: 1 ; b) a CDR-L2 comprising or consisting of an amino acid sequence of SEQ ID NO: 2; and c) a CDR-L3 comprising or consisting of an amino acid sequence of SEQ ID NO: 3; and a heavy chain variable region comprising d) a CDR-H1 comprising or consisting of an amino acid sequence of SEQ ID NO: 5; e) a CDR-H2 comprising or consisting of an amino acid sequence of SEQ ID NO: 8; and f) a CDR-H3 comprising or consisting of an amino acid sequence of SEQ ID NO: 9.
- the antibody-drug conjugate comprises an antibody or antigen- binding fragment that comprises: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12 and an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16; or b) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12 and an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 15; or c) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 11 and an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16; or d) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 11 and an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 17; or
- the antibody-drug conjugate comprises an antibody or antigen-binding fragment that comprises: a) an immunoglobulin light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 12; and b) an immunoglobulin heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 16.
- the antibody-drug conjugate of the present disclosure comprises the antibody or antigen-binding fragment thereof of the present disclosure which is linked to a conjugating unit, such as bis-mPEG of Formula C” functionalized with a glutamic acid (bis-mPEG-Glu), which is linked to a linker comprising or consisting of Val-Cit-PAB-DMEDA, which is linked to the active agent PNU159682, wherein the conjugating unit is also linked to a functional unit, such as 6’-amino-p- cyclodextrin, via the glutamic acid comprised in the conjugating unit.
- a conjugating unit such as bis-mPEG of Formula C” functionalized with a glutamic acid (bis-mPEG-Glu)
- bis-mPEG-Glu glutamic acid
- the conjugating unit is also linked to a functional unit, such as 6’-amino-p- cyclodextrin, via the glutamic acid comprised in the conjugating unit.
- the antibody-drug conjugate of the present disclosure comprises the antibody or antigen-binding fragment thereof of the present disclosure which is linked to a drug conjugate as illustrated in Figure 1.
- the ADCs directed against integrin alphalO as described herein are useful for the delivery of active agents, such as therapeutic or cytotoxic agents to cells expressing alphalO betal and thus for the treatment of a range of diseases and disorder associated with cells expressing integrin alpha10beta1.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of the ADC, as described herein, together with a pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.
- compositions may be prepared in a manner known in the art that is sufficiently storage stable and suitable for administration to humans and/or animals.
- the pharmaceutical compositions may be lyophilised, e.g. through freeze drying, spray drying, spray cooling, or through use of particle formation from supercritical particle formation.
- pharmaceutically acceptable we mean a non-toxic material that does not decrease the effectiveness of the anti-integrin alphalO ADC.
- pharmaceutically acceptable buffers, carriers or excipients are well-known in the art (see Remington's Pharmaceutical Sciences, 18th edition, A.R Gennaro, Ed., Mack Publishing Company (1990) and handbook of Pharmaceutical Excipients, 3rd edition, A. Kibbe, Ed., Pharmaceutical Press (2000), the disclosures of which are incorporated herein by reference).
- buffer is intended to mean an aqueous solution containing an acid-base mixture with the purpose of stabilising pH.
- Pharmaceutically acceptable buffers are well known in the art.
- diluting is intended to mean an aqueous or non-aqueous solution with the purpose of diluting the agent in the pharmaceutical preparation.
- adjuvant is intended to mean any compound added to the formulation to increase the biological effect of the agent of the invention.
- the adjuvant may be one or more of zinc, copper or silver salts with different anions, for example, but not limited to fluoride, chloride, bromide, iodide, thiocyanate, sulfite, hydroxide, phosphate, carbonate, lactate, glycolate, citrate, borate, tartrate, and acetates of different acyl composition.
- the adjuvant may also be cationic polymers such as cationic cellulose ethers, cationic cellulose esters, deacetylated hyaluronic acid, chitosan, cationic dendrimers, cationic synthetic polymers such as poly(vinyl imidazole), and cationic polypeptides such as polyhistidine, polylysine, polyarginine, and peptides containing these amino acids.
- cationic polymers such as cationic cellulose ethers, cationic cellulose esters, deacetylated hyaluronic acid, chitosan, cationic dendrimers, cationic synthetic polymers such as poly(vinyl imidazole), and cationic polypeptides such as polyhistidine, polylysine, polyarginine, and peptides containing these amino acids.
- the excipient may be one or more of carbohydrates, polymers, lipids and minerals.
- carbohydrates include lactose, glucose, sucrose, mannitol, and cyclodextrines, which are added to the composition, e.g., for facilitating lyophilisation.
- polymers are starch, cellulose ethers, cellulose carboxymethylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, alginates, carageenans, hyaluronic acid and derivatives thereof, polyacrylic acid, polysulphonate, polyethylenglycol/polyethylene oxide, polyethyleneoxide/polypropylene oxide copolymers, polyvinylalcohol/polyvinylacetate of different degree of hydrolysis, and polyvinylpyrrolidone, all of different molecular weight, which are added to the composition, e.g., for viscosity control, for achieving bioadhesion, or for protecting the lipid from chemical and proteolytic degradation.
- lipids are fatty acids, phospholipids, mono-, di-, and triglycerides, ceramides, sphingolipids and glycolipids, all of different acyl chain length and saturation, egg lecithin, soy lecithin, hydrogenated egg and soy lecithin, which are added to the composition for reasons similar to those for polymers.
- minerals are talc, magnesium oxide, zinc oxide and titanium oxide, which are added to the composition to obtain benefits such as reduction of liquid accumulation or advantageous pigment properties.
- the ADCs of the present disclosure may be formulated into any type of pharmaceutical composition known in the art to be suitable for the delivery thereof.
- the ADCs of the present disclosure or pharmaceutical compositions comprising the ADCs may be administered via any suitable route known to those skilled in the art.
- possible routes of administration include parenteral (intravenous, subcutaneous, and intramuscular), topical, ocular, nasal, pulmonar, buccal, oral, vaginal and rectal.
- administration from implants is possible.
- the pharmaceutical compositions are administered parenterally, for example, intravenously, intracerebroventricularly, intraarticularly, intraarterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion techniques. They are conveniently used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multidose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- the ADCs of the present disclosure are administered in situ in the body of a subject during a surgery, to the damaged site.
- the ADCs of the present disclosure are administered intravenously.
- the ADCs of the present disclosure are administered subcutaneously. In one embodiment the ADCs of the present disclosure are administered intracranially or intracerebrally.
- compositions will be administered to a patient in a pharmaceutically effective amount.
- the amount of a compound may vary depending on its specific activity. Suitable dosage amounts may contain a predetermined quantity of active composition calculated to produce the desired therapeutic effect in association with the required diluent.
- a therapeutically effective amount can be determined by the ordinarily skilled medical or veterinary worker based on patient characteristics, such as age, weight, sex, condition, complications, other diseases, etc., as is well known in the art.
- the administration of the pharmaceutically effective dose can be carried out both by single administration in the form of an individual dose unit, or else several smaller dose units, and also by multiple administrations of subdivided doses at specific intervals. Alternatively, the dose may be provided as a continuous infusion over a prolonged period.
- the ADCs targeting integrin alpha10beta1 described herein may be administered alone or in combination with other therapeutic agents.
- the ADCs targeting integrin alphalO described herein may be administered in combination with a range of anti-cancer agents, such as antimetabolites, alkylating agents, anthracyclines and other cytotoxic antibiotics, vinca alkyloids, anti-microtubule/anti-mitotic agents, histone deacetylase inhibitors, kinase inhibitors, peptide antibiotics, platinum-based antineoplastics, etoposide, taxanes, topoisomerase inhibitors, antiproliferative immunosuppressants, corticosteroids, sex hormones and hormone antagonists, cytotoxic antibiotics and other therapeutic agents.
- anti-cancer agents such as antimetabolites, alkylating agents, anthracyclines and other cytotoxic antibiotics, vinca alkyloids, anti-microtubule/anti-mitotic agents, histone deacet
- the ADC of the present disclosure is administered in conjunction with additional reagents and/or therapeutics that may increase the functional efficiency of the ADC, such as established or novel drugs that increase lysosomal membrane permeability, thereby facilitating molecular entry from the lysosome interior to the cytoplasm, or drugs that increase the permeability of the blood-brain barrier.
- additional reagents and/or therapeutics that may increase the functional efficiency of the ADC, such as established or novel drugs that increase lysosomal membrane permeability, thereby facilitating molecular entry from the lysosome interior to the cytoplasm, or drugs that increase the permeability of the blood-brain barrier.
- the present disclosure provides for a pharmaceutical composition
- a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to another aspect of the disclosure, or the antibody-drug conjugate according to the present disclosure, and a pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.
- the present disclosure provides for a method for delivery an active agent to a cell expressing alpha10beta1 comprising administering to said cell the antibody-drug conjugate as described herein, or the pharmaceutical composition according to another aspect of the disclosure, such that the active agent is delivered to said cell.
- the present disclosure provides for the antibody-drug conjugate or the pharmaceutical composition as described herein, for use as a medicament.
- the present disclosure provides for the antibody-drug conjugate or the pharmaceutical composition as described herein, for use in treating a patient with a disease or disorder associated with cells expressing integrin alphalO.
- the cells expressing integrin alphalO are malignant cells or tumor-associated cells, such as cancer associated fibroblast (CAFs), stromal cells, stem cells and/or stem-like cells and/or cells of the tumor microenvironment such as tumor-associated macrophages (TAMs), immune cells, endothelial cells.
- CAFs cancer associated fibroblast
- TAMs tumor-associated macrophages
- immune cells endothelial cells.
- the present disclosure provides for the antibody-drug conjugate or the pharmaceutical composition as described herein, for use in the treatment of a neoplastic disease or disorder.
- the neoplastic disease or disorder is solid tumor or a lymphoma.
- the neoplastic disease or disorder is a cancer.
- the cancer is selected from the group consisting of breast cancer, brain cancer, cancer of the Central Nervous System (CNS), lung cancer, prostate cancer, pancreatic cancer, skin cancer, lymphoma, sarcoma, rhabdoid tumor, cholangiocarcinoma, or a metastasis of any one of said cancer forms.
- cholangiocarcinoma can be an intrahepatic bile duct cancer, a perihilar bile duct cancer or a distal (extrahepatic) bile duct cancer.
- the breast cancer is selected from the group consisting of triple negative breast cancer and inflammatory breast cancer.
- Triple negative breast cancer is selected from the group consisting of basal-like 1 breast cancer, basal-like 2 breast cancer, claudin-low breast cancer, metaplastic breast cancer (MBC), interferon-rich breast cancer, immunomodulatory breast cancer, mesenchymal breast cancer, mesenchymal stem-like breast cancer, luminal androgen receptor breast cancer and unstable breast cancer.
- the lung cancer is selected from the group consisting of squamous cell lung carcinoma, lung adenocarcinoma, large cell lung carcinoma and small-cell lung carcinoma.
- the prostate cancer is small cell neuroendocrine carcinoma (SCNC) or castrate-resistant prostate cancer (CRPC).
- SCNC small cell neuroendocrine carcinoma
- CRPC castrate-resistant prostate cancer
- the pancreatic cancer is an exocrine tumor or an endocrine tumor, such as wherein the pancreas cancer is an exocrine tumor selected from the group consisting of ductal adenocarcinoma, acinar cell carcinoma, adeno-squamous carcinoma, intraductal papillary mucinous neoplasm (IPMN) and Pancreatic intraepithelial neoplasia.
- IPMN intraductal papillary mucinous neoplasm
- Pancreatic intraepithelial neoplasia Pancreatic intraepithelial neoplasia.
- the pancreatic cancer is an endocrine tumor selected from the group consisting of neuroendocrine tumor, gastrinoma, glucaganoma, insulinoma, somatostatinoma, VIPoma, and non-functional Islet cell tumor, such as wherein the neuroendocrine tumor is a grade I, grade II or grade III pancreatic cancer.
- the brain cancer and/or the cancer of the CNS is selected from the group consisting of tumours of neuroepithelial tissue, tumours of cranial and paraspinal nerves, tumours of the meninges, tumours of the haematopoietic system, and tumours of the sellar region.
- the brain cancer and/or the cancer of the CNS is an astrocytic tumour, such as an astrocytic tumor selected from Glioblastoma, Giant cell glioblastoma, Pilocytic astrocytoma, Pilomyxoid astrocytoma, Subependymal giant cell astrocytoma, Pleomorphic xanthoastrocytoma, Diffuse astrocytoma, Anaplastic astrocytoma, Gliosarcoma, Gliomatosis cerebri.
- an astrocytic tumour such as an astrocytic tumor selected from Glioblastoma, Giant cell glioblastoma, Pilocytic astrocytoma, Pilomyxoid astrocytoma, Subependymal giant cell astrocytoma, Pleomorphic xanthoastrocytoma, Diffuse astrocytoma, Anaplastic astro
- the brain cancer and/or the cancer of the CNS is an embryonal tumour such as a neuroblastoma, a medulloblastoma and/or a rhabdoid tumour of the brain.
- the brain cancer and/or the cancer of the CNS is an ependymal tumour, such as an ependymal tumour selected from Subependymoma, Myxopapillary ependymoma, Ependymoma, and Anaplastic ependymoma.
- an ependymal tumour selected from Subependymoma, Myxopapillary ependymoma, Ependymoma, and Anaplastic ependymoma.
- the tumours of neuroepithelial tissue are selected from: a) Astrocytic tumours selected from Pilocytic astrocytoma, Pilomyxoid astrocytoma, Subependymal giant cell astrocytoma, Pleomorphic xanthoastrocytoma, Diffuse astrocytoma, Anaplastic astrocytoma, Glioblastoma, Giant cell glioblastoma, Gliosarcoma, Gliomatosis cerebri, and b) Oligodendroglial tumours selected from Oligodendroglioma and Anaplastic oligodendroglioma, and c) Oligoastrocytic tumours selected from Oligoastrocytoma and Anaplastic oligoastrocytoma, and d) Ependymal tumours selected from Subependymoma, Myxopapillary ependymoma, Ependymo
- the tumours of cranial and paraspinal nerves are selected from: a) Schwannoma, b) Neurofibroma, c) Perineurioma, and d) Malignant peripheral nerve sheath tumour (MPNST).
- the tumours of the meninges are selected from: a) Tumours of meningothelial cells, selected from Meningioma, Atypical meningioma, Anaplastic meningioma, b) Mesenchymal tumours selected from Lipoma, Angiolipoma, Hibernoma, Liposarcoma, Solitary fibrous tumour, Fibrosarcoma, Malignant fibrous histiocytoma, Leiomyoma, Leiomyosarcoma, Rhabdomyoma, Rhabdomyosarcoma, Chondroma, Chondrosarcoma, Osteoma, Osteosarcoma, Osteo-chondroma, Haemangioma, Epithelioid hemangioendothelioma, Haemangiopericytoma, Anaplastic haemangiopericytoma, and Angiosarcoma, Kaposi Sarcoma, Ewing Sarcoma, Kaposi Sarcom
- the tumours of the haematopoietic system are selected from: a) Malignant Lymphomas, Plasmocytoma, and b) Granulocytic sarcoma
- the tumours of the sellar region are selected from: a) Craniopharyngioma, b) Granular cell tumour, c) Pituicytoma, and d) Spindle cell oncocytoma of the adenohypophysis.
- the skin cancer is a melanoma, such as malignant melanoma.
- the sarcoma is an osteosarcoma.
- the the antibody-drug conjugate as described herein inhibits cell division and/or inhibits cell proliferation and/or inhibits cell survival and/or induces cell death of cells expressing integrin alpha10beta1.
- the described effect of the antibodydrug conjugate may result from blocking of microtubule polymerization, resulting in cell cycle arrest and inducing caspase-3-dependent apoptosis.
- the cell proliferation and/or cell survival may be the result of the antibody-mediated cytotoxicity and/or binding to the epitope antigen of cancer cells and inhibits downstream signal transduction of antigen receptor which can lead to inhibition of cell survival and proliferation and induce cell apoptosis.
- the antibody-drug conjugate as described herein may irreversibly bind to DNA and cause strong inter strand cross-linking that prevents DNA strand separation, thus destroying necessary DNA metabolic processes and finally leading to cell deaths.
- the antibody-drug conjugate as described herein inhibits spreading of cancer cells to other sites within the same organ, as well as to other organs.
- the antibody-drug conjugate as described herein inhibits metastasis of cancer, wherein the cancer is any one mentioned herein, such as wherein the cancer is a cancer characterized by expression of integrin alpha10beta1.
- the the antibody-drug conjugate as described herein induces bystander effect which results in cell death of integrin alphal 0-negative cancer cells.
- cytotoxic agent that is conjugated to the antibody by either a cleavable or non-cleavable linker has the capacity to diffuse across cell membranes after the release from the antibody and thereby cause killing of neighbouring cells.
- the cytotoxic agent may be either the cytotoxic agent only or the cytotoxic agent with a part of the linker that has the bystander kill capacity.
- the capacity to diffuse across cell membranes is related to the hydrophobicity of the cytotoxic agent or the combination of the cytotoxic agent and the linker.
- bystander killing or “bystander effect” refers to the killing of target negative cells in the presence of target-positive cells, wherein killing of target-negative cells is not observed in the absence of target-positive cells.
- Cell-to-cell contact, or at least proximity between target-positive and target- negative cells enables bystander killing. This type of killing is distinguishable from “off-target killing,” which refers to the indiscriminate killing of target-negative cells. “Off-target killing” may be observed in the absence of targetpositive cells.
- the antibody-drug conjugate or the pharmaceutical composition according to other aspect of present disclosure is administered parenterally, for example, intravenously, intracerebroventricularly, intraarticularly, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intramuscularly or subcutaneously, by infusion techniques, or in situ.
- parenterally for example, intravenously, intracerebroventricularly, intraarticularly, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intramuscularly or subcutaneously, by infusion techniques, or in situ.
- in situ it can be understood that the antibody-drug conjugate or the pharmaceutical composition may be administered at the site of neoplasm where abnormal cells have not spread beyond where they first formed, or it can be understood that the a the antibody-drug conjugate or the pharmaceutical composition may be administered at the site, from which a neoplasm has been surgically removed.
- the antibody-drug conjugate or the pharmaceutical composition is administered in combination with one or more further agents, such as one or more further therapeutic agents.
- the present disclosure provides for a method for treatment of a disease characterized by expression of integrin alphal Obetal in a subject, comprising administering to the subject the antibody-drug conjugate or the pharmaceutical composition according to other aspects of the present disclosure described herein.
- the present disclosure provides for a use of the antibody-drug conjugate or the pharmaceutical composition according other aspects of the disclosure for treatment of a disease.
- the present disclosure provides for a kit comprising the antibody-drug conjugate or the pharmaceutical composition as described herein, optionally further comprising means for administering the antibody-drug conjugate to a subject and/or instructions for use.
- Aim To generate human antibody sequence segments to create humanised antibody variants.
- Structural models of the mouse antibody Tm-Ab regions were produced. Based on structure analysis, sequences of humanized variants, likely to be essential for the binding properties of the antibody, were selected and analysed in silico. Human sequence segments were identified both within and outside the CDR regions. Selected sequence segments were assembled to generate complete humanized V region sequences that were devoid of, or reduced in, significant T cell epitopes to avoid immunogenicity.
- VH1 to VH7 The design resulted in seven heavy chain (VH1 to VH7) and three light chain (VK1 to VK3) sequences that were used for gene synthesis and expression in mammalian cells (Table 1). Seven VH were combined with 3 VK generating 21 different humanized variants.
- Table 1 Summary table of the 21 humanized antibody variants including a chimeric antibody (Th-AbO).
- Aim To generate small scale batches of antibodies for lead candidate selection.
- Aim To select five lead candidates from the 21 humanized variants based on integrin a10 binding properties.
- the mouse myoblast cell line C2C12 overexpressing either human integrin alpha10beta1 (C2C12apha10) or human integrin alpha11beta1 (C2C12alpha11) were used to study antibody binding and specificity.
- the C2C12 cells were incubated (100 000 cells/sample) with the integrin alphalO antibodies at 1 pg/ml for 30 min followed by a secondary antibody for 30 min followed by analysis by flow cytometry.
- results The results showed that the chimeric antibody Th-AbO as well as humanized antibody variants Th-Ab1 - Th-Ab15 had the best binding affinity to C2C12alpha10 cells (data not shown). None of the antibodies showed binding to the control C2C12alpha11 cells (data not shown). Additionally, risk analysis data from the sequence design process suggested that the antibodies Th-Ab9, Th-Ab11 , Th-Ab12, Th-Ab14 and Th-Ab15 have lower immunogenicity than the other variants (data not shown), therefore, these antibodies were selected for further internalization and thermal stability studies.
- Aim To investigate the internalization level of the five antibody candidates in integrin alphalO expressing cell lines.
- the mouse myoblast cell line C2C12 overexpressing the integrin alpha10beta1 (C2C12alpha10) was used in the internalization assay.
- the cells 500 000 cells/sample) were incubated with the five lead humanized antibodies as well as the chimeric antibody Th-AbO and the original mouse antibody Tm-Ab (1 pg/sample) for 30 min at 4 °C.
- the cells were then washed with PBS containing 2% FBS and incubated at 37 °C for 90 minutes or 4 hours and then incubated with a secondary antibody for 20 min in the dark at 4 °C.
- the cells were washed twice with PBS prior to analysis of internalization rate (%) by flow cytometry.
- Aim To rank the top five humanized antibody variants based on stability.
- Thermal stability analysis of the humanized antibody lead candidates was performed using an UncleTM biostability platform and software. Samples for each variant were formulated in PBS and Sypro Orange at a final concentration of 0.5 mg/ml. Samples were subjected to a thermal ramp from 25 - 95 °C, with a ramp rate of 0.3 °C/minute and excitation at 473 nm. Monitoring of static light scattering (SLS) at 473 nm allowed the detection of protein aggregation, and calculation of T agg .
- SLS static light scattering
- Aim To generate and characterize Th-Ab12-ADC.
- ADCs used for these studies were generated using a well-established conjugation approach.
- targeting antibodies were subjected to conjugation to a “anthracycline” type of payload (Glu-(Val-cit-PAB-DMEDA- PNU159682)-6’-amino-p-cyclodextrin) by mild reduction of interchain disulfides, followed by a cysteine rebridging approach to produce ADCs with highly homogeneous drug-to-antibody ratios (DAR) of around 4.
- DAR drug-to-antibody ratios
- ADCs were generated with a disulfide rebridging conjugation technology (bison PEG according to Formula C” and functionalized with a glutamic acid), a cytotoxic payload PNU159682 (Formula X) and a cleavable linker Val-Cit-PAB-DMEDA (Formula Y).
- the structure is shown in Figure 1.
- An average DAR of the ADCs is 4.
- the percentage of the monomeric purity were over 95% for all the ADCs and the percentage of the free payload species were not detectable. Endotoxin levels were below 0.1 EU/mg.
- Integrin alpha10beta1 expressing cells C2C12alpha10
- integrin alpha11beta1 overexpressing cells C2C12alpha11
- BT549 and Hs578T triple negative breast cancer cells
- A204 rhabdoid tumour
- SJSA-1 osteosarcoma
- U3046MG and U3054 MG human patient-derived glioblastoma cells
- the cells were incubated with the IgG 1 isotype control Ctrl-ADC at 100 nM or Th-Ab12-ADC at different concentrations (0.5, 1 , 5, 10, 50, 100, 1000 nM) for 30 min at 4°C and were then incubated with a secondary antibody for 30 min at 4°C prior to the analysis by flow cytometry.
- the binding EC50 for each cell line is within a range of 0.9 - 2.69 nM ( Figure 3B - H). There was no binding to C2C12alpha11 cells suggesting that Th- Ab12-ADC is specifically binding to integrin alphalO ( Figure 3A).
- Th-Ab12-ADC binds to integrin alphalO in a specific manner and with high affinity, which supports its potential for successful drug development.
- Aim To evaluate the in vitro efficacy of Th-Ab12-ADC in different cell lines.
- Cells were seeded either as monolayer (C2C12alpha10, C2C12alpha11 and A204) or as spheres (BT549, Hs578T, U3046MG, U3054MG and SJSA-1) and treated with the IgG 1 isotype control Ctrl-ADC or Th-Ab12-ADC at different concentrations (0.13, 0.77, 4.6, 27.8, 167, 100 nM) for 5 days (C2C12alpha10, C2C12alpha11, A204 and SJSA-1) or 10 days (BT549, Hs578T, U3046MG and U3054MG).
- the WST-1 assay is based on the cleavage of tetrazolium salt WST-1 for formazan by cellular mitochondrial dehydrogenases. The larger the number of viable cells, the higher the activity of the mitochondrial dehydrogenases, and in turn the greater the amount of formazan dye formed.
- Th-Ab12-ADC was found to induce integrin alphalO specific toxicity in C2C12alpha10, TNBC and GB cell lines with high potency.
- Aim To study the internalization rate of Th-Ab12-ADC in various integrin alphalO expressing cell lines.
- C2C12alpha10, BT549, Hs578T, U3046MG and U3054MG cells were used.
- the cells 500 000 cells/sample) were incubated with Th-Ab12-ADC or unconjugated antibody Th-Ab12 (1 pg/0.1 ml) for 30 min on ice.
- the cells were then washed with PBS containing 2% FBS and incubated at 37 °C for 90 minutes or 4 hours and then incubated with a secondary antibody containing Alexa 488 fluorochrome for 20 min at 4 °C.
- the cells were washed twice with PBS prior to the analysis of internalization rate (%) by flow cytometry.
- Th-Ab12-ADC was internalized by 50 - 60% within 4 h of incubation in all the cell lines tested ( Figure 4). Overall, the internalization level was higher at 4 h than at 90 min. The internalization of Th-Ab12-ADC was slightly better than unconjugated Th- Ab12 in TNBC and GB cell lines ( Figure 4).
- C2C12alpha10 cells (9 000 cells/well) were seeded and cultured as monolayer in a 6-well culture plate and incubated with ADCs at concentration of 0.02 nM. On day 5, the cells were harvested and stained with propidium iodide (PI) before analysis of cell cycle distribution using Propidium Iodide Flow Cytometry Kit (Abeam, ab139418) according to the manufacturer’s instructions.
- PI propidium iodide
- Th-Ab12-ADCs bind to the C2C12alpha10 cells, is internalized, and subsequently cleaved to release the cell toxin. The released toxin then causes DNA damage and lead to cell death/apoptosis.
- C2C12alpha10 and C2C12alpha11 cells (with no integrin alphalO expression) were used.
- C2C12alpha10 and C2C12alpha11 cells were seeded and cultured in a 6-well culture plate at 12 000 and 8 000 cells/well, respectively.
- the cells were seeded at 20 000 cells/well.
- Th-Ab12-ADC and Ctrl-ADC were added to the wells at a concentration of 0.02 nM. Viable cells were detached from the plate after 5 days of culture, and the cell number in each well was determined using a cell counter.
- the ratio of C2C12alpha10 and C2C12alpha11 cells the cells (100 000/sample) were stained with integrin alphalO antibody conjugated with Alexa 647 and analyzed by a flow cytometry.
- Th-Ab12-ADC has good bystander effect which means that Th-Ab12-ADC can also induce cell death in nearby cells without integrin alphalO expression. This can be beneficial for the treatment of solid tumours with heterogeneous integrin alphalO expression.
- Aim To evaluate the in vivo efficacy of Th-Ab12-ADC in glioblastoma cell line U3046MG-derived xenograft nude mouse model.
- Th-Ab12-ADC Treatment with Th-Ab12-ADC inhibited tumour growth compared to the Ctrl-ADC and PBS ( Figure 8A and C). The inhibitory effect was seen with both doses (0.75 mg/kg and 1 .5 mg/kg). The ADC treatments did not affect the body weights of the mice compared to the PBS group ( Figure 8B and D).
- the results show that Th-Ab12-ADC exhibits good in vivo efficacy in glioblastoma U3046MG xenograft nude mouse model. This suggests that Th-Ab12- ADC has the potential to become an effective treatment for glioblastoma and other aggressive cancers expressing integrin alpha10beta1.
- the mouse myoblast cell line C2C12 transduced with integrin a10 vector (C2C12a10) was cultured in Dulbecco’s Modified Eagle Medium (Gibco) supplemented with 10% FBS (Gibco) and Antibiotic-Antimycotic (100 U/rnL, Gibco).
- the C2C12a10 cells were selected using G418 (1 mg/ml, Gibco).
- Antibodies Primary antibodies: Th-Ab12 (supernatant VH4VK3 variant) and Tm-Ab- A647 (conjugated to AlexaFluor A647, thus Tm-Ab-A647; also corresponding to: "an alternative mouse monoclonal antibody against integrin alphalO” used in Examples 2 , 3, 4, and 9 of WO 2020/212416, and to the antibody against integrin alphalO used in Munksgaard Thoren M., 2019 [8] both for FACS and conjugated to Saporin) at 10 pg/ml.
- Secondary antibody Donkey anti human IgG Alexa 488 (T011), 1:1000 for Th- Ab12.
- Table 3 Cells were incubated with a primary antibody against integrin a10 (Th-Ab12 or Tm-Ab- A647) at a concentration of 10 pg/ml. After 30 min incubation with primary antibody, cells were washed twice with FACS buffer; DPBS (Hyclone) containing 1% FBS (Gibco) and 0,1 % sodium azide (G Bioscience). Secondary antibody or donkey anti-human IgG AF488 was then added according to the table above and incubated for 30 min. After incubation cells were washed twice with FACS buffer. Finally, a third antibody was added to samples 4 and 5 for the last incubation according to the table above. Samples 4 and 5 were also washed twice prior to the analysis using flow cytometry.
- a primary antibody against integrin a10 Th-Ab12 or Tm-Ab- A647
- samples with only one integrin a10 antibody are used as single stain reference to see how the primary antibody binds to the target in absence of competition.
- the samples with successive addition of the two antibodies against integrin a10 are the samples that will be competing for binding of target in this assay. Samples 1 and 6 are used to determine background staining.
- Th-Ab12 has a higher affinity towards C2C12a10 cells than Tm-Ab.
- CDR-L1 Variable light chain complementarity-determining region 1
- SEQ ID NO: 2 KVSNRFS
- CDR-L2 Variable light chain complementarity-determining region 2 (CDR-L2) SEQ ID NO: 3: SQSTHVPYT
- CDR-L3 Variable light chain complementarity-determining region 3
- CDR-H1 Variable heavy chain complementarity-determining region 1
- CDR-H1 Variable heavy chain complementarity-determining region 1
- CDR-H1 Variable heavy chain complementarity-determining region 1
- CDR-H1 Variable heavy chain complementarity-determining region 1
- SEQ ID NO: 8 WIFPGSGRTYYSEKFRG
- CDR-H2 Variable heavy chain complementarity-determining region 2
- CDR-H3 Variable heavy chain complementarity-determining region 3
- VH2 Variable heavy chain - VH2
- VH4 Variable heavy chain - VH4
- VH5 Variable heavy chain - VH5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne un conjugué anticorps-médicament alpha10 d'intégrine et des utilisations médicales associées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22193257 | 2022-08-31 | ||
EP22193257.7 | 2022-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024047172A1 true WO2024047172A1 (fr) | 2024-03-07 |
Family
ID=83149219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/073919 WO2024047172A1 (fr) | 2022-08-31 | 2023-08-31 | Conjugué anticorps-médicament d'intégrine alpha10 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024047172A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007107774A2 (fr) * | 2006-03-22 | 2007-09-27 | Cartela R & D Ab | Nouvelles méthodes de diagnostic et de traitement |
WO2016133449A1 (fr) * | 2015-02-16 | 2016-08-25 | Xintela Ab | Détection et traitement de tumeurs malignes dans le snc |
WO2020212416A1 (fr) | 2019-04-15 | 2020-10-22 | Xintela Ab | Intégrine alpha10 et formes de cancer agressives |
-
2023
- 2023-08-31 WO PCT/EP2023/073919 patent/WO2024047172A1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007107774A2 (fr) * | 2006-03-22 | 2007-09-27 | Cartela R & D Ab | Nouvelles méthodes de diagnostic et de traitement |
WO2016133449A1 (fr) * | 2015-02-16 | 2016-08-25 | Xintela Ab | Détection et traitement de tumeurs malignes dans le snc |
WO2020212416A1 (fr) | 2019-04-15 | 2020-10-22 | Xintela Ab | Intégrine alpha10 et formes de cancer agressives |
Non-Patent Citations (32)
Title |
---|
"handbook of Pharmaceutical Excipients", 2000, PHARMACEUTICAL PRESS |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY |
"Uniprot", Database accession no. 075578 |
AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948 |
ANGOV, BIOTECHNOL. J, vol. 6, no. 6, 2011, pages 650 - 659 |
BOCKERMANN, RJARNUM, SRICHTER, JPENNINGTON, D ET AL.: "10 Integrin Expression Is Up-Regulated on Fibroblast Growth Factor-2-Treated Mesenchymal Stem Cells with Improved Chondrogenic Differentiation Potential", STEM CELLS DEV, vol. 16, 2007, pages 965 - 978, XP009105829, DOI: 10.1089/scd.2007.0049 |
BUMBACA, DBOSWELL, C.AFIELDER, P.JKHAWLI, L.A: "Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics", AAPS J, vol. 14, 2012, pages 554 - 558, XP035074786, DOI: 10.1208/s12248-012-9369-y |
CAMPER, L.; HOLMVALL, K.; WANGNERUD, C.; ASZODI, A.; LUNDGREN-ÅKERLUND, E.: "Distribution of the collagen-binding integrin a10β1 during mouse development.", CELL TISSUE RES., vol. 306, 2001, pages 107 - 116 |
DEAN, A.QLUO, STWOMEY, J.DZHANG, B: "Targeting cancer with antibody-drug conjugates: Promises and challenges", MABS, 2021, pages 13 |
DONDELINGER ET AL.: "Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition", FRONT. IMMUNOL, 16 October 2018 (2018-10-16) |
DRUG DISCOVERY TODAY, vol. 10, 2005, pages 23 - 33 |
EXPERT. OPIN. BIOL. THER., vol. 5, 2005, pages 783 - 797 |
FEBS J, vol. 274, 2007, pages 86 - 95 |
GEBAUERSKERRA, CURR OPIN CHEM BIOL, vol. 13, no. 3, 2009, pages 245 - 255 |
GIUGLIANO, FCORTI, CTARANTINO, PMICHELINI, FCURIGLIANO, G: "Bystander effect of antibody-drug conjugates: fact or fiction?", CURR. ONCOL. REP, 2022 |
GULLBERG, D.ELUNDGREN-AKERLUND, E: "Cottagen-binding I domain integrins - What do they do?", PROG. HISTOCHEM. CYTOCHEM, vol. 37, 2002, pages 3 - 54 |
INNOVATIONS PHARMAC. TECHNOL., 2006, pages 27 - 30 |
J. PHARMACOL. EXP. THER, vol. 318, 2006, pages 803 - 809 |
KABAT ET AL., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 1987 |
LEFRANC ET AL.: "IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains", DEV COMP IMMUNOL, vol. 29, no. 3, 2005, pages 185 - 203, XP004657549, DOI: 10.1016/j.dci.2004.07.003 |
LI ET AL.: "Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells", MOL BIOL REP, vol. 45, no. 6, December 2018 (2018-12-01), pages 2907 - 2912, XP036644906, DOI: 10.1007/s11033-018-4351-0 |
LUNDGREN-AKERLUND, EASZODI, A: "Integrin a10131: a collagen receptor critical in skeletal development", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 819, 2014, pages 61 - 71, XP009516506 |
MASOUMI KATARZYNA CHMIELARSKA ET AL: "Integrin ?10-Antibodies Reduce Glioblastoma Tumor Growth and Cell Migration", vol. 13, no. 5, 9 March 2021 (2021-03-09), pages 1184, XP009539690, ISSN: 2072-6694, Retrieved from the Internet <URL:https://www.mdpi.com/2072-6694/13/5/1184> [retrieved on 20210309], DOI: 10.3390/CANCERS13051184 * |
MASOUMI, K.CHUANG, XME, WMIRKOV, AMUNKSGAARD, MMASSOUMI, RLUNDGREN-AKERLUND, E: "Integrin a 10-Antibodies Reduce Glioblastoma Tumor Growth and Cell Migration", CANCERS (BASEL), vol. 13, 2021, pages 1184, XP009539690, DOI: 10.3390/cancers13051184 |
METH. MOL. BIOL., vol. 352, 2007, pages 95 - 109 |
NAT. BIOTECHNOL., vol. 22, 2004, pages 575 - 582 |
NAT. BIOTECHNOL., vol. 23, 2005, pages 1556 - 1561 |
NYGREN, FEBS J, vol. 275, 2008, pages 2668 - 2676 |
THOREN, M.M.; MASOUMI, K.C.; KRONA, C.; HUANG, X.; KUNDU, S.; SCHMIDT, L: "a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration Proliferation, and Survival", CANCERS (BASEL), vol. 11, 2019, pages 587 |
TRENDS. BIOTECHNOL., vol. 23, 2005, pages 514 - 522 |
UVEBRANT, K.; REIMER RASMUSSON, L.; TALTS, J.; ALBERTON, P.; ASZODI, A.,LUNDGREN-AKERLUND, E.: "Integrin α10β1-selected Equine MSCs have Improved Chondrogenic Differentiation, Immunomodulatory and Cartilage Adhesion", ANN STEM CELL RES, vol. 2, 2019, pages 001 - 009 |
VISVADERLINDEMAN, NAT REV CANCER, vol. 8, 2008, pages 755 - 768 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110869393B (zh) | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 | |
JP5841046B2 (ja) | 制御された血清中薬物動態を有するヒトタンパク質スキャフォールド | |
ES2932777T3 (es) | Sustratos de matriptasa y activador del plasminógeno-u y otros motivos escindibles y métodos de uso de los mismos | |
EP3353198B1 (fr) | Molécules à échafaudage à base de fibronectine se liant à la glypicane-3 | |
BR112020005212A2 (pt) | conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição. | |
US20240277863A1 (en) | Antibody-urease conjugates for therapeutic purposes | |
Sauter et al. | Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck | |
CN110770256A (zh) | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 | |
US20190375837A1 (en) | Immunocytokine combination therapy | |
JP2019535232A (ja) | 抗psma抗体、その使用及びそのコンジュゲート | |
CN114269389B (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
JP2019527561A (ja) | 抗体、その使用及びそのコンジュゲート | |
KR20130042466A (ko) | 두경부 편평 세포 암종의 치료에 사용하기 위한 cd44에 대한 단클론 항체 | |
US10947316B2 (en) | Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof | |
US20220306751A1 (en) | Antigen-binding protein constructs and uses thereof | |
US20220298260A1 (en) | Antigen-binding protein constructs and uses thereof | |
WO2024047172A1 (fr) | Conjugué anticorps-médicament d'intégrine alpha10 | |
ES2831651T3 (es) | Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento | |
US20220288219A1 (en) | Antigen-binding protein constructs and uses thereof | |
WO2023166170A1 (fr) | Anticorps anti-intégrine alpha10 | |
TW202346338A (zh) | pH依賴性抗硫酸化醣胺聚醣抗體及抗體藥物複合體 | |
JP2024507275A (ja) | 細胞間接着分子1(icam1)抗体薬物抱合体およびそれらの使用 | |
JP2022546387A (ja) | 細胞間接着分子1(icam1)抗体薬物抱合体およびそれらの使用 | |
CN118667006A (zh) | 靶向ror1的抗体、包含其的抗体偶联药物、制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23764617 Country of ref document: EP Kind code of ref document: A1 |